[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Pivotal Health Solutions, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":204},{"warningLetters":4,"total":203},[5,31,50,72,93,105,123,145,166,186],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},2895,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-02-01T14:20:00Z\">02\u002F01\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-22T04:00:00Z\">10\u002F22\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapplied-health-solutions-inc-616778-10222021\">Applied Health Solutions, Inc.\u003C\u002Fa>","Office of Human and Animal Food Operations - Division IV West","New Drug\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>William Evans\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Applied Health Solutions, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>11231 N 84th Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Scottsdale\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Food Operations - Division IV West\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 22, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n\u003Cstrong>Ref: CMS Case # 616778\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Evans:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fstore.appliedhealth.com in July-August 2021 and has determined that you take orders there for the Applied Health Solutions brand products B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, and PowerZyme Prime, and the NutriBiotic brand products Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate. We also reviewed your website at the Internet address https:\u002F\u002Fappliedhealth.com, which directs consumers to your website https:\u002F\u002Fstore.appliedhealth.com to purchase your products. The claims on your websites establish these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Examples of the website claims that establish the intended use of the products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>B Complex product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F), which hyperlinks to the product webpage for B Complex:\u003C\u002Fp>\n\n\u003Cp>• “Prevent MRSA Infection . . . Annihilate infections before they start -Strengthen Your Immunity[.] Anything that can be done to boost your immune system will benefit you when you come in contact with this bacteria. . . . make sure you are getting plenty of immune boosting vitamins. . . . B-complex . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Daily Detox product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the Daily Detox product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fcollections\u002Fdetox-cleansing-support\u002Fproducts\u002Fdaily-detox-toxin-binding-agents):\u003C\u002Fp>\n\n\u003Cp>• “Broccoli Extract – BroccoSinolate [an ingredient in Daily Detox] . . . rich in . . . glucosinolates . . . Glucosinolates . . . help lower cancer risks and protect against cardiovascular disease. Another benefit . . . is the ability to help fight bacterial, viral, and fungal infections.”\u003C\u002Fp>\n\n\u003Cp>On the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F), which hyperlinks to the product webpage for Daily Detox:\u003C\u002Fp>\n\n\u003Cp>• “Regular use of Daily Detox offers powerful antioxidant protection against seasonal colds and flu.”\u003C\u002Fp>\n\n\u003Cp>• “NATURAL TREATMENT: Good riddance “SuperBug”! These nutrients contain anti-microbial and anti-bacterial properties: Applied Health’s Daily Detox . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>PowerZyme Prime product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the PowerZyme Prime ingredients webpage (https:\u002F\u002Fappliedhealth.com\u002Fpowerzyme-digestive-enzymes\u002Fpowerzyme-ingredients\u002F):\u003C\u002Fp>\n\n\u003Cp>• “Lysozyme [an ingredient in PowerZyme Prime] . . . Documented in human studies to inhibit the growth of Candida albicans.”\u003C\u002Fp>\n\n\u003Cp>• “Serratia peptidase [an ingredient in PowerZyme Prime] . . . exhibits well documented fibrinolytic (prevention of blood clots), anti-inflammatory, and anti-edematous (prevents swelling of tissues from water entrapment – edema) activities and lessens the viscosity of exudates (a fluid of protein and cellular elements that escapes blood vessels due to inflammation and settles in nearby tissues).”\u003C\u002Fp>\n\n\u003Cp>On the “Chronic Candida Syndrome” blog post (https:\u002F\u002Fappliedhealth.com\u002Fchronic-candida-syndrome\u002F):\u003C\u002Fp>\n\n\u003Cp>• “What causes Candidiasis? . . . Other contributing factors to Candida imbalance are . . . Lack of digestive enzymes . . .” [the phrase “digestive enzymes” hyperlinks to the PowerZyme Prime product webpage]\u003C\u002Fp>\n\n\u003Cp>On the “Chronic Candida Syndrome Part 2” blog post (https:\u002F\u002Fappliedhealth.com\u002Fchronic-candida-syndrome-part-2\u002F):\u003Cbr>\n\u003Cbr>\n• “Incidence of Candidiasis is rapidly increasing. Several reasons for this are: . . . Lack of proper digestive enzymes in our diet. . . . As always, we prefer to recommend more holistic methods for our readers. However, remember that it is important to rotate even natural therapies, because resistant strains of Candida mutate easily. . . . Nutrients and antioxidants that support the immune system are also important, such as: Digestive Enzymes . . .” [the PowerZyme Prime product is also referred to as “Digestive Enzymes” on the PowerZyme Prime product webpage]\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Grapefruit Seed Extract CapsulesPlus product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the Grapefruit Seed Extract CapsulesPlus product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fproducts\u002Fnutribiotic-grapefruit-seed-extract-with-echinacea-and-artemisia-annua):\u003C\u002Fp>\n\n\u003Cp>• “It is effective against pathogens because it belongs to a family of compounds known as quaternary compounds.”\u003C\u002Fp>\n\n\u003Cp>• “Additional information to consider on Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus] is available at: Grapefruit Seed Extract for Cold\u002FFlu Season:\u003Cbr>\nhttps:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F . . . Prevent MRSA Infection: https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Grapefruit Seed Extract Liquid Concentrate product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the Grapefruit Seed Extract Liquid Concentrate product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fproducts\u002Fnutribiotic-grapefruit-seed-extract-liquid):\u003C\u002Fp>\n\n\u003Cp>• “Additional information to consider on Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract Liquid Concentrate]: Grapefruit Seed Extract for Cold\u002FFlu Season: https:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F . . . Prevent MRSA Infection: https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F . . .”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>Grapefruit Seed Extract Liquid Concentrate and Grapefruit Seed Extract CapsulesPlus products:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F):\u003C\u002Fp>\n\n\u003Cp>• “NATURAL TREATMENT: Good riddance “SuperBug”! These nutrients contain anti-microbial and anti-bacterial properties . . . Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate]”\u003C\u002Fp>\n\n\u003Cp>On the “Benefits of Grapefruit seed Extract” webpage (https:\u002F\u002Fappliedhealth.com\u002Fbenefits-of-grapefruit-seed-extract\u002F), which hyperlinks to the Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate product webpages:\u003C\u002Fp>\n\n\u003Cp>• “Grapefruit Seed Extract (GSE) [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate] . . . Used as a . . . antimicrobial product, it is known to be highly effective for fighting infection . . . Even in studies comparing its effectiveness to chlorine bleach, isopropyl alcohol, and colloidal silver, GSE has been found to be superior as an antimicrobial.”\u003C\u002Fp>\n\n\u003Cp>• “. . . research showing the effectiveness of GSE against AIDS.”\u003C\u002Fp>\n\n\u003Cp>• “All over the world, GSE has been used for killing a wide variety of bacteria (such as: Salmonella, E. coli, Staph and Strep germs), viruses, herpes, parasites, and fungi, including Candida. It is effective against more than 800 bacterial and viral strains, 100 strains of fungus, as well as a large number of single-cell and multi-celled parasites.”\u003C\u002Fp>\n\n\u003Cp>• “. . . the antimicrobial properties of GSE . . .”\u003C\u002Fp>\n\n\u003Cp>• “. . . antifungal properties of GSE have made it an important part of successful anti-Candida programs – a fact that has linked the names Candida and Grapefruit Seed Extract.”\u003C\u002Fp>\n\n\u003Cp>• “‘In the treatment of intestinal protozoan infections . . . [ellipsis in original] drugs are generally so toxic that they cannot be administered for prolonged periods of time, whereas GSE can be administered for weeks or months; prolonged treatment being essential for the cure of chronic protozoan infections . . . [ellipsis in original]’”\u003C\u002Fp>\n\n\u003Cp>• “To aid in the anti-Candida treatment, . . . GSE should be taken between meals. . . .”\u003C\u002Fp>\n\n\u003Cp>• “. . . a variety of other ailments can be helped by GSE, such as: . . .\u003C\u002Fp>\n\n\u003Cp>&nbsp; − AIDS – An increasing number of HIV positive people are able to improve their immune system by using GSE to fight viruses, bacteria, fungi, Candida, or parasites. . . .\u003Cbr>\n&nbsp; − Colds, flus, viruses – Take 10-15 drops, or 1-2 capsules\u002Ftablets, 3 times a day, at the first signs of cold or flu. . . .\u003Cbr>\n&nbsp; − Chronic Fatigue Syndrome – To generally build up immune system, gradually increase GSE amount to the recommended dosage for colds, flus, and viruses. . . .\u003Cbr>\n&nbsp; − Diarrhea – Use 15 to 20 drops in juice every four hours; no more than 60 drops per day. For parasites, higher doses may be necessary. . . .\u003Cbr>\n&nbsp; − Parasites . . .\u003Cbr>\n&nbsp; − Traveler’s Diarrhea (Montezuma’s Revenge) – Use 1-2 drops of GSE in a glass of water each day as a preventative. . . .\u003Cbr>\n&nbsp; − Ulcers . . .”\u003C\u002Fp>\n\n\u003Cp>On the “Grapefruit Seed Extract Rx for Cold and Flu Season” webpage (https:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F), which hyperlinks to the Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate product webpages:\u003C\u002Fp>\n\n\u003Cp>• “Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate] RX for Cold and Flu Season”\u003C\u002Fp>\n\n\u003Cp>• “A Must-Have For Every Home During Cold and Flu Season”\u003C\u002Fp>\n\n\u003Cp>• “Whether it’s a sore throat, earache, viral infection, intestinal problem, or anything else related to a virus, fungus, or bad bacteria, if you are the main caregiver in your home, Grapefruit Seed Extract is a must-have for your cupboard.”\u003C\u002Fp>\n\n\u003Cp>• “. . . it is ‘Grapefruit’ Seed Extract (abbreviated as GSE or GFSE) that works as a natural antibiotic with anti-viral, anti-bacterial, and anti-fungal properties.”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Internal Uses”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Fight Colds, Flus, Viruses”\u003Cbr>\n&nbsp; − “Reach for the GSE at the first symptoms of flu or cold.”\u003Cbr>\n&nbsp; − “Traveler’s Diarrhea – As a preventative when traveling in areas with questionable water, mix 1 or 2 drops GSE in each glass of water, or on your toothbrush to disinfect and help prevent Traveler’s diarrhea.”\u003Cbr>\n&nbsp; − “Diarrhea – If you do experience a case of diarrhea, take 15 to 25 drops GSE every 3 to 4 hours in water or juice – no more than 75 drops per day. Or, 2 capsules\u002Ftablets (no more than 6 per day) every 4 hours.”\u003Cbr>\n&nbsp; − “Parasites . . . Use the same amount of GSE as for diarrhea, with possibly increasing to a maximum of 5 doses per day.”\u003Cbr>\n&nbsp; − “There have been anecdotal reports of GSE helping some serious illnesses, such as Chronic Fatigue Syndrome, AIDS, and even Cancer.”\u003Cbr>\n\u003Cbr>\n• “There are many more uses for GSE. Once you have successfully used it for something simple, like fighting a cold, you may find yourself reaching for it, regularly, whenever you find a need for its anti-viral, anti-fungal, and anti-bacterial properties.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>CellRenewPRO product:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the CellRenewPRO product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fcollections\u002Fjoint-soft-tissue-support\u002Fproducts\u002Fcellrenew-pro-hydrolyzed-collagen-type-ii):\u003C\u002Fp>\n\n\u003Cp>• “CellRenew PRO provides multi-dimensional nutritional components vital for repairing connective soft tissue (joints, skin, cardiovascular, etc.).”\u003C\u002Fp>\n\n\u003Cp>On the CellRenewPRO supplement facts and monograph webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-pro-defined):\u003C\u002Fp>\n\n\u003Cp>• “CellRenew Pro is Ultimate Joint Repair”\u003C\u002Fp>\n\n\u003Cp>• “CellRenew PRO provides multi-dimensional nutritional components vital for repairing connective soft tissue (joints, skin, cardiovascular, etc.).”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>CellRenewPRO and CellRenewSTS products:\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>On the CellRenewPRO (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-pro-defined) and CellRenewSTS (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-sts-supplement-facts-and-monograph) supplement facts and monograph webpages:\u003C\u002Fp>\n\n\u003Cp>• “CellRenew contains Hydrolyzed Collagen Type II derived from 100% pure chicken sternal cartilage. As an abundant source of naturally-occurring Hyaluronic Acid and Chondroitin Sulfates, Collagen Type II is easily absorbed to restore joint and cartilage health.”\u003C\u002Fp>\n\n\u003Cp>• “It is an absorbable hydrolyzed collagen type II product . . . that . . . relieves joint discomfort and increases mobility.”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Research”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Collagen Type II (CCII) [an ingredient in CellRenewPRO and CellRenewSTS] . . . can suppress pro-inflammatory activity to reduce joint discomfort and restore cartilage health. CCII from chicken sternal cartilage was shown to reduce chronic joint inflammation . . .”\u003Cbr>\n&nbsp; − “A three-month study recruited 60 patients with chronic joint inflammation to take CCII or a placebo. Results indicated CCII alleviated swollen and tender joints in the treatment group. Four patients in the treatment group had a complete remission of chronic joint inflammation.”\u003Cbr>\n&nbsp; − “Similarly, a pilot-study recruited female subjects with joint pain to take Hydrolyzed Collagen Type II for 42 days. Subjects reported a significant improvement in joint mobility and decrease in joint pain and stiffness.”\u003Cbr>\n&nbsp; − “CCII is evidenced to be effective among adolescents with chronic joint inflammation. A pilot-study administered CCII to 10 adolescent patients with chronic joint inflammation for 12 weeks. Eight patients experienced a reduction in swollen and tender joints. A similar pilot-study recruited nine adolescents with chronic joint inflammation to take an oral Collagen Type II, finding the supplement . . . reduced joint inflammation.”\u003Cbr>\n&nbsp; − “Chondroitin Sulfate (Component of Collagen Type II) [an ingredient in CellRenewPRO and CellRenewSTS] Naturally found in sternal chicken Collagen Type II, chondroitin sulfate has anti-inflammatory activity that reduces joint swelling, maintains synovial fluid levels, and spacing between the joints. Further, chondroitin sulfate reduces the proliferation of proteins to reduce joint inflammation.”\u003Cbr>\n&nbsp; − “A one-year study recruited 42 patients with knee pain to take chondroitin sulfate or a placebo. Subjects taking chondroitin sulfate had greater joint mobility and less pain, when compared to the placebo group.”\u003Cbr>\n&nbsp; − “A three-month study recruited 110 patients with knee pain to take chondroitin sulfate or a placebo finding supplementation improved knee function, reduced pain, and maintained joint space in the knee.”\u003Cbr>\n&nbsp; − “Researchers suggested chondroitin sulfate and glucosamine could repair and regenerate cartilage . . .”\u003Cbr>\n&nbsp; − “Hyaluronic Acid (Component of Collagen Type II) [an ingredient in CellRenewPRO and CellRenewSTS] . . . Studies have suggested hyaluronic acid has anti-inflammatory activity that suppresses pro-inflammatory and pain mechanisms in the body.”\u003Cbr>\n&nbsp; − “Researchers found that HA inhibited inflammatory cytokine activity in mice with inflamed joints. A similar study reviewed the effect of HA on acute and chronic inflammation in rats, finding HA suppressed inflammatory reactions . . .”\u003C\u002Fp>\n\n\u003Cp>On the homepage for the https:\u002F\u002Fappliedhealth.com website:\u003C\u002Fp>\n\n\u003Cp>• “How do you help knee pain? . . . CellRenew PRO is Extreme Knee Protection”\u003C\u002Fp>\n\n\u003Cp>• “CellRenew Additional Links . . . CellRenew Collagen Type II and Knee Pain . . . Is Collagen Type II A Cure For Arthritis And Heart Disease . . .”\u003Cbr>\n\u003Cbr>\n• In the response to the question “What is CellRenew?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Unlike other protocols for arthritis symptoms, whether prescription or natural, CellRenew is guaranteed for results.”\u003Cbr>\n&nbsp; − “It contains naturally occurring Hyaluronic Acid and Chondroitin Sulfate. The results of a human clinical trial using this material showed significant improvements in the reduction of joint swelling, tenderness, and pain, as well as successful increases in mobility.”\u003C\u002Fp>\n\n\u003Cp>• In the response to the question “Who is a good candidate to take CellRenew?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Although studies have shown that many different conditions respond to Collagen Type II, the conditions that have shown the greatest response are rheumatoid arthritis and osteoarthritis. If you have grown weary of traditional protocols that only cover-up symptoms and neglect to address the root cause, then you are an excellent candidate to begin a program of Collagen Type II.”\u003Cbr>\n&nbsp; − “CellRenew is also used as a preventative measure for athletes who . . . are looking for a way to maintain healthy joints prior to the onset of osteoarthritis.”\u003C\u002Fp>\n\n\u003Cp>• In response to the question “What will it do for me?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Collagen Type II (CTII) [an ingredient in CellRenewPRO and CellRenewSTS] has been suggested to offer significant benefits for some types of arthritis. . . . Rheumatoid arthritis (RA) is the most well known of the autoimmune types of arthritis. In the case of RA, the collagen in the joints is attacked.”\u003Cbr>\n&nbsp; − “Depending on the particular type of arthritis you experience, CTII goes to work in different ways. If you suffer from RA, CTII acts as an oral tolerization agent, instructing the body to stop the immune response to the collagen in the joints. . . . For those suffering from osteoarthritis, CTII provides the critical building blocks that restore a healthy state to the cartilage in the joints.”\u003Cbr>\n&nbsp; − “CellRenew is made from chicken sternal cartilage that contains the highest level of naturally occurring anti-inflammatory proteoglycans (Hyaluronic Acid and Chondroitin Sulfate A) of any other material tested, including shark cartilage. It is important to note that the combination of the proteoglycans and the Collagen Type II proteins . . . provide the building blocks required to rebuild lost cartilage to restore the joint to a normal state.”\u003C\u002Fp>\n\n\u003Cp>• In response to the question “What do the studies show?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “The results of a recent double-blind, placebo-controlled, clinical trial has proved the benefits of Collagen Type II for treating the symptoms of pain and immobility associated with arthritis. . . . report an 89.9% positive response rate, within 45 days, for the participants who consumed at least 2000 mg of Collagen Type II per day.”\u003Cbr>\n&nbsp; − “[R]eported having successfully treated more than 50 patients, starting in 1974, with osteoarthritis, rheumatoid arthritis, psoriasis, and many other ailments. . . .”\u003Cbr>\n&nbsp; − “Of the different types of cartilage tested, the one with the highest level of Collagen Type II, anti-inflammatory proteoglycans (the healing properties) was chicken sternal cartilage. CellRenew is 100% chicken sternal cartilage.”\u003C\u002Fp>\n\n\u003Cp>• In response to the question “What else is it good for?”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Besides the better-known associations with osteoarthritis and rheumatoid arthritis, it has also been suggested that Collagen Type II might benefit heart disease, psoriasis, progressive myopia, and some other autoimmune diseases.”\u003C\u002Fp>\n\n\u003Cp>• In response to the question “How long before I improve?”:&nbsp;&nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “Although some people have noticed an improvement with their symptoms after only a week or two of starting a CellRenew program, many take between 4 and 6 weeks. . . . some forms of arthritis symptoms tend to respond faster – on average – than other forms. For instance, we do know that rheumatoid arthritis sufferers have a tendency to respond faster . . .”\u003C\u002Fp>\n\n\u003Cp>Under the heading “CellRenew Customer Stories” on the homepage for the https:\u002F\u002Fappliedhealth.com website:\u003C\u002Fp>\n\n\u003Cp>• “‘I have been taking CellRenew since May of 2003. . . . This product has kept my arthritis at bay. . . .’”\u003C\u002Fp>\n\n\u003Cp>• “‘[T]hank you for the dramatic results I have experienced in the first three weeks of taking CellRenew. For the past twenty years, I have been living with severe lower back pain. I was diagnosed with a degenerative disc disorder in the L2, L3, and L4 vertebrae. . . . CellRenew has improved my quality of life one thousand percent.’”\u003C\u002Fp>\n\n\u003Cp>• “‘Fourteen months ago – diagnosed with scoliosis, osteoarthritis of the spine and degenerative disc disease – my active life was gone . . . I was in excruciating pain most of the time. . . . On the xray [sic], my spine looked like a rock pile. . . . Enter CellRenew, and within one month, the improvement was incredible. That was four months ago. . . . I have my life back. I know that CellRenew works!’”\u003C\u002Fp>\n\n\u003Cp>• “‘I wanted to tell you all about how thrilled I am with CellRenew. I have been taking CellRenew for just over a year now. I have not had a single ache or pain in at least 10 months. I have experienced no side effects, except for one good side effect. I have changed my eyeglass prescription, twice! Both times were for the better! My eyesight is improving. . . .’”\u003C\u002Fp>\n\n\u003Cp>Under the heading “In the beginning…” on the homepage for the https:\u002F\u002Fappliedhealth.com website:\u003C\u002Fp>\n\n\u003Cp>• “Bill Evans, President, Applied Health . . . my lifestyle was finally catching up to me . . . due to rapidly progressing arthritis. . . . Instead of a future filled with the pursuit of my favorite activities, and dreams of conquering the Bucket List, I only saw the prospect of surgeries, painkillers, and physical therapy. I decided there had to be a better way than knee replacement and a cocktail of medications. A year later, in 1997, we started Applied Health and introduced our first Collagen-based, joint support product using hydrolyzed collagen type II . . . We called it CellRenew, and over 20 years later, we still have devoted users . . . [ellipsis in original] myself among them.”\u003C\u002Fp>\n\n\u003Cp>On the “CellRenew Hydrolyzed Collagen Type II Technical Outline” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fcellrenew-technical-outline\u002F):\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Key Product Highlights\u002FBullets”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “CellRenew is so effective that the raw material has been awarded two United States Patents . . . for the treatment of connective tissue disorder, osteoarthritis, degenerative joint disease, joint defects, vascular disease, and cartilage injuries . . .”\u003Cbr>\n&nbsp; − “May help support proper inflammatory function due to its chondroitin sulfate content . . .”\u003Cbr>\n&nbsp; − “May possibly support proper wound healing due to its potent hyaluronic acid content . . .”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Studies and Mechanisms of action”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “CellRenew and its components can have a powerful impact on joints and conditions associated with abnormal joint function. One study [footnote omitted] published in 2000 entitled ‘Role of collagen hydrolysate in bone and joint disease’, reviews how collagen can be a powerful tool in helping with osteoarthritis and even osteoporosis. . . . Mechanism of action: The components of CellRenew . . . lower the chance for deterioration.”\u003Cbr>\n&nbsp; − “‘[H]yaluronan preparations have been shown to decrease pain and increase function in patients with osteoarthritis of the knee.’ Mechanism of action: Hyaluronic Acid seems to work through several mechanisms of action including restoration of more normal synovial fluid with improved viscoelasticity, effects on cartilage biosynthesis and degradation, anti-inflammatory effects, and direct analgesic effects.”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Patent Claims”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “2. A method for treating an individual with a connective tissue disorder . . .”\u003Cbr>\n&nbsp; − “3. The method of claim 2, wherein said connective tissue disorder is selected from the group consisting of degenerative joint diseases, joint defects, osteoarthritis, polychondritis, vascular disease, cartilage injuries, progressive myopia and Menier’s [sic] disease.”\u003C\u002Fp>\n\n\u003Cp>On the “Effects of Collagen Type II For Subjective Pain Relief” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fhydrolyzed-collagen-clinical-trial\u002F), which contains a hyperlink to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\u003C\u002Fp>\n\n\u003Cp>• The following quote appears after a summary of a study on the effects of Collagen Type II (an ingredient in CellRenewPRO and CellRenewSTS) on the course of pain syndromes, including rheumatoid arthritic pain, osteoarthritis joint pain, post surgical joint pain, post traumatic pain, fibrositis, gouty arthritis, lumbosacral pain with\u002Fwithout radicular pain, and cervical spine pain with\u002Fwithout radicular pain: “‘The results were overwhelmingly positive for pain relief and the side benefits were remarkable! This product has changed my life significantly.’”\u003C\u002Fp>\n\n\u003Cp>On the “Is Collagen Type II A Cure For Arthritis And Heart Disease?” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fcollagen-type-ii-cure-arthritis-heart-disease\u002F), which hyperlinks to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Collagen Type II [an ingredient in CellRenewPRO and CellRenewSTS] and Arthritis”:\u003C\u002Fp>\n\n\u003Cp>&nbsp; − “. . . 50 million Americans suffer from some form of arthritis, either rheumatoid or osteoarthritis, as well as a variety of other arthritic conditions. . . . Could it be that one nutritional medicine called collagen type II can ameliorate both disorders in an effective way?”\u003Cbr>\n&nbsp; − “It may turn out that the natural components of cartilage hold the greatest promise of ameliorating both arthritis and heart disease.”\u003Cbr>\n&nbsp; − “If collagen type II is derived from chicken sternal cartilage, from chicks six to eight weeks old, it contains the greatest number of anti-inflammatory and joint supporting proteoglycans. These proteoglycans include glucosamine sulfate which has over 30 years of double-blind, placebo-controlled studies indicating that it actually helps to rebuild the cartilage in arthritis joints.”\u003Cbr>\n&nbsp; − “[I]t contains a high concentration of chondroitin sulfate A, which is a powerful anti-inflammatory . . .”\u003Cbr>\n&nbsp; − “[C]ollagen type II also contains a powerful, newly discovered antioxidant proteoglycan called cartilage matrix glycoprotein (CMGP), which can help reduce the oxidative damage to the joint.”\u003Cbr>\n&nbsp; − “When people suffer from arthritis, there is a selective destruction of collagen type II in the joint cartilage itself. Scientists know that this particular component of cartilage is being attacked by white blood cells and somehow this activates the immune system in the rheumatoid arthritic patient to develop antibodies to collagen type II. This then sets up an immune response to all of the cartilage that is degenerating in the body. Thus, both wrists hurt, both knees hurt, the hips, the back, etc.”\u003Cbr>\n&nbsp; − “The question now becomes how does collagen type II turn off the immune system in the rheumatoid arthritic. The answer is that collagen type II’s effectiveness is accomplished through ‘oral tolerance.’”\u003Cbr>\n&nbsp; − “. . . investigate the side effects of chicken sternal collagen type II being fed to arthritic rats. . . . By the second or third months the rats no longer displayed any symptoms of arthritis. There was a profound amelioration of the disease.”\u003Cbr>\n&nbsp; − “. . . studied ten people with severe rheumatoid arthritis. They eliminated the standard therapies such as NSAIDS and methotrexate and fed the patients pure collagen type II derived from chicken sternal cartilage. At the end of the second month, six of the ten patients showed substantial improvement and one showed a complete regression of the disease that lasted 26 months with no side effects.”\u003Cbr>\n&nbsp; − “. . . conducted a phase II trial on 59 patients with, again, severe active rheumatoid arthritis. . . . What is interesting is that those who were off all drugs and taking collagen type II showed very significant stabilization and improvement, while those on placebos continued to deteriorate. In fact, four collagen type II patients showed a complete resolution of the disease . . .”\u003Cbr>\n&nbsp; − “We see that oral ingestion of collagen type II may well prove to be the most effective natural means of arthritis management regardless of the form of the disease.”\u003Cbr>\n&nbsp; − “. . . this is precisely why it works in osteoarthritis . . . collagen type II has such a high concentration of glucosamine and chondroitin . . .”\u003Cbr>\n&nbsp; − “In lieu [sic] of the fact that there are no side effects with collagen type II, this would seem to be the product of choice when suffering from any form of arthritic condition.”\u003Cbr>\n&nbsp; − “. . . collagen II components are truly chondro-protective agents because they . . . reprogram destructive chondrocytes and cytokines, reducing inflammation . . . protect the surface of the cartilage from oxidative damage . . . act as a powerful anti-inflammatory and pain modulator.”\u003C\u002Fp>\n\n\u003Cp>• Under the heading “Collagen Type II [an ingredient in CellRenewPRO and CellRenewSTS] and Heart Disease”:\u003Cbr>\n\u003Cbr>\n&nbsp; − “Medicines such as aspirin and NSAIDS, as well as natural therapeutics such as fish liver oil or antiarthritic herbs, cannot compete with the overall biochemical power of collagen type II.”\u003Cbr>\n&nbsp; − “. . . collagen type II is 14.2 percent chondroitin sulfate A. . . . Chondroitin sulfate A (CSA) has a powerful antithrombogenic or anticoagulant affect, which, in essence, prevents blood clots and has been shown to reduce the incidence of stroke.”\u003Cbr>\n&nbsp; − “. . . CSA literally reduced the cholesterol and other lipids in the blood and actually ‘cleared’ cholesterol from the lining of arteries, including the aorta.”\u003Cbr>\n&nbsp; − “This indicates a 600 percent reduction in the incidence of fatal heart attacks simply by taking oral CSA on a daily basis . . .”\u003Cbr>\n&nbsp; − “Collagen type II has also found some support in the research for the amelioration of autoimmune disease caused by breast implant poisoning, as well as amelioration of Menier’s [sic] disease and progressive myopia.”\u003C\u002Fp>\n\n\u003Cp>On the “The Village of Long Life” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fhyaluronic-acid-abc-news\u002F), which hyperlinks to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\u003C\u002Fp>\n\n\u003Cp>• “. . . hyaluronic acid [a component of the Hydrolyzed Collagen II ingredient in the CellRenewPRO and CellRenewSTS products] has been used for years in eye surgery as a shock absorber to protect the retina, and has been proven effective in lubricating arthritic joints.”\u003C\u002Fp>\n\n\u003Cp>• “But HA has been shown to have wound-healing and tissue-reconstruction applications . . .”\u003C\u002Fp>\n\n\u003Cp>On the “Collagen Type II for Arthritis Pain Relief” blog post (https:\u002F\u002Fappliedhealth.com\u002Fcollagen-type-ii-for-arthritis-pain-relief\u002F):\u003C\u002Fp>\n\n\u003Cp>• “Collagen Type II [an ingredient in the CellRenewPRO and CellRenewSTS products] for Arthritis Pain Relief”\u003C\u002Fp>\n\n\u003Cp>• “Does Collagen Type II relieve osteoarthritis? Research says, yes.”\u003C\u002Fp>\n\n\u003Cp>• “Collagen type II (CTII) is an effective source for alleviating joint stiffness and increasing mobility. Several studies have found CTII reduces joint pain in rheumatoid arthritis, but a new study . . . found that it is also an effective treatment for osteoarthritis.”\u003C\u002Fp>\n\n\u003Cp>• “Researchers recruited 52 subjects with osteoarthritis in the knees to take CTII or a glucosamine\u002Fchondroitin combination for 90 days. . . . Overall, CTII reduced joint pain by 40%.”\u003C\u002Fp>\n\n\u003Cp>• “How does collagen type II alleviate joint pain? CTII is the primary form of collagen naturally found in joint cartilage. The body needs CTII to rebuild connective tissue. Supplementing with a superior form of collagen can help reduce inflammation and the breakdown of collagen in the body. For the best absorption, choose a hydrolyzed collagen type II to restore joint health.”\u003C\u002Fp>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your Applied Health Solutions brand products B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, and the NutriBiotic brand products Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, Grapefruit Seed Extract CapsulesPlus, and Grapefruit Seed Extract Liquid Concentrate products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087, to the attention of Compliance Officer Carrie Jolly or by email to carrie.jolly@fda.hhs.gov. If you need additional information or have questions concerning any products distributed through your website, please contact CO Jolly at carrie.jolly@fda.hhs.gov or (303) 236-9656.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>E. Mark Harris\u003Cbr>\nDenver District Director &amp; Program Division Director\u003Cbr>\nOffice of Human and Animal Food Operations −\u003Cbr>\nDivision IV West\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nWilliam Evans\n\nRecipient Title\n\nPresident\n\nApplied Health Solutions, Inc.\n\n11231 N 84th Street\n\nScottsdale, AZ 85260\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Food Operations - Division IV West\n\nUnited States\n\nOctober 22, 2021\n\nWARNING LETTER\n\nRef: CMS Case # 616778\n\nDear Mr. Evans:\n\nThis is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fstore.appliedhealth.com in July-August 2021 and has determined that you take orders there for the Applied Health Solutions brand products B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, and PowerZyme Prime, and the NutriBiotic brand products Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate. We also reviewed your website at the Internet address https:\u002F\u002Fappliedhealth.com, which directs consumers to your website https:\u002F\u002Fstore.appliedhealth.com to purchase your products. The claims on your websites establish these products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of the website claims that establish the intended use of the products as drugs include, but may not be limited to, the following:\n\nB Complex product:\n\nOn the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F), which hyperlinks to the product webpage for B Complex:\n\n• “Prevent MRSA Infection . . . Annihilate infections before they start -Strengthen Your Immunity[.] Anything that can be done to boost your immune system will benefit you when you come in contact with this bacteria. . . . make sure you are getting plenty of immune boosting vitamins. . . . B-complex . . .”\n\nDaily Detox product:\n\nOn the Daily Detox product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fcollections\u002Fdetox-cleansing-support\u002Fproducts\u002Fdaily-detox-toxin-binding-agents):\n\n• “Broccoli Extract – BroccoSinolate [an ingredient in Daily Detox] . . . rich in . . . glucosinolates . . . Glucosinolates . . . help lower cancer risks and protect against cardiovascular disease. Another benefit . . . is the ability to help fight bacterial, viral, and fungal infections.”\n\nOn the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F), which hyperlinks to the product webpage for Daily Detox:\n\n• “Regular use of Daily Detox offers powerful antioxidant protection against seasonal colds and flu.”\n\n• “NATURAL TREATMENT: Good riddance “SuperBug”! These nutrients contain anti-microbial and anti-bacterial properties: Applied Health’s Daily Detox . . .”\n\nPowerZyme Prime product:\n\nOn the PowerZyme Prime ingredients webpage (https:\u002F\u002Fappliedhealth.com\u002Fpowerzyme-digestive-enzymes\u002Fpowerzyme-ingredients\u002F):\n\n• “Lysozyme [an ingredient in PowerZyme Prime] . . . Documented in human studies to inhibit the growth of Candida albicans.”\n\n• “Serratia peptidase [an ingredient in PowerZyme Prime] . . . exhibits well documented fibrinolytic (prevention of blood clots), anti-inflammatory, and anti-edematous (prevents swelling of tissues from water entrapment – edema) activities and lessens the viscosity of exudates (a fluid of protein and cellular elements that escapes blood vessels due to inflammation and settles in nearby tissues).”\n\nOn the “Chronic Candida Syndrome” blog post (https:\u002F\u002Fappliedhealth.com\u002Fchronic-candida-syndrome\u002F):\n\n• “What causes Candidiasis? . . . Other contributing factors to Candida imbalance are . . . Lack of digestive enzymes . . .” [the phrase “digestive enzymes” hyperlinks to the PowerZyme Prime product webpage]\n\nOn the “Chronic Candida Syndrome Part 2” blog post (https:\u002F\u002Fappliedhealth.com\u002Fchronic-candida-syndrome-part-2\u002F):\n\n• “Incidence of Candidiasis is rapidly increasing. Several reasons for this are: . . . Lack of proper digestive enzymes in our diet. . . . As always, we prefer to recommend more holistic methods for our readers. However, remember that it is important to rotate even natural therapies, because resistant strains of Candida mutate easily. . . . Nutrients and antioxidants that support the immune system are also important, such as: Digestive Enzymes . . .” [the PowerZyme Prime product is also referred to as “Digestive Enzymes” on the PowerZyme Prime product webpage]\n\nGrapefruit Seed Extract CapsulesPlus product:\n\nOn the Grapefruit Seed Extract CapsulesPlus product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fproducts\u002Fnutribiotic-grapefruit-seed-extract-with-echinacea-and-artemisia-annua):\n\n• “It is effective against pathogens because it belongs to a family of compounds known as quaternary compounds.”\n\n• “Additional information to consider on Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus] is available at: Grapefruit Seed Extract for Cold\u002FFlu Season:\n\nhttps:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F . . . Prevent MRSA Infection: https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F . . .”\n\nGrapefruit Seed Extract Liquid Concentrate product:\n\nOn the Grapefruit Seed Extract Liquid Concentrate product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fproducts\u002Fnutribiotic-grapefruit-seed-extract-liquid):\n\n• “Additional information to consider on Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract Liquid Concentrate]: Grapefruit Seed Extract for Cold\u002FFlu Season: https:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F . . . Prevent MRSA Infection: https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F . . .”\n\nGrapefruit Seed Extract Liquid Concentrate and Grapefruit Seed Extract CapsulesPlus products:\n\nOn the “Prevent MRSA Infection” blog post (https:\u002F\u002Fappliedhealth.com\u002Fprevent-mrsa-infection\u002F):\n\n• “NATURAL TREATMENT: Good riddance “SuperBug”! These nutrients contain anti-microbial and anti-bacterial properties . . . Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate]”\n\nOn the “Benefits of Grapefruit seed Extract” webpage (https:\u002F\u002Fappliedhealth.com\u002Fbenefits-of-grapefruit-seed-extract\u002F), which hyperlinks to the Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate product webpages:\n\n• “Grapefruit Seed Extract (GSE) [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate] . . . Used as a . . . antimicrobial product, it is known to be highly effective for fighting infection . . . Even in studies comparing its effectiveness to chlorine bleach, isopropyl alcohol, and colloidal silver, GSE has been found to be superior as an antimicrobial.”\n\n• “. . . research showing the effectiveness of GSE against AIDS.”\n\n• “All over the world, GSE has been used for killing a wide variety of bacteria (such as: Salmonella, E. coli, Staph and Strep germs), viruses, herpes, parasites, and fungi, including Candida. It is effective against more than 800 bacterial and viral strains, 100 strains of fungus, as well as a large number of single-cell and multi-celled parasites.”\n\n• “. . . the antimicrobial properties of GSE . . .”\n\n• “. . . antifungal properties of GSE have made it an important part of successful anti-Candida programs – a fact that has linked the names Candida and Grapefruit Seed Extract.”\n\n• “‘In the treatment of intestinal protozoan infections . . . [ellipsis in original] drugs are generally so toxic that they cannot be administered for prolonged periods of time, whereas GSE can be administered for weeks or months; prolonged treatment being essential for the cure of chronic protozoan infections . . . [ellipsis in original]’”\n\n• “To aid in the anti-Candida treatment, . . . GSE should be taken between meals. . . .”\n\n• “. . . a variety of other ailments can be helped by GSE, such as: . . .\n\n− AIDS – An increasing number of HIV positive people are able to improve their immune system by using GSE to fight viruses, bacteria, fungi, Candida, or parasites. . . .\n\n− Colds, flus, viruses – Take 10-15 drops, or 1-2 capsules\u002Ftablets, 3 times a day, at the first signs of cold or flu. . . .\n\n− Chronic Fatigue Syndrome – To generally build up immune system, gradually increase GSE amount to the recommended dosage for colds, flus, and viruses. . . .\n\n− Diarrhea – Use 15 to 20 drops in juice every four hours; no more than 60 drops per day. For parasites, higher doses may be necessary. . . .\n\n− Parasites . . .\n\n− Traveler’s Diarrhea (Montezuma’s Revenge) – Use 1-2 drops of GSE in a glass of water each day as a preventative. . . .\n\n− Ulcers . . .”\n\nOn the “Grapefruit Seed Extract Rx for Cold and Flu Season” webpage (https:\u002F\u002Fappliedhealth.com\u002Fgrapefruit-seed-extract-rx-for-cold-and-flu-season\u002F), which hyperlinks to the Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate product webpages:\n\n• “Grapefruit Seed Extract [an ingredient in Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate] RX for Cold and Flu Season”\n\n• “A Must-Have For Every Home During Cold and Flu Season”\n\n• “Whether it’s a sore throat, earache, viral infection, intestinal problem, or anything else related to a virus, fungus, or bad bacteria, if you are the main caregiver in your home, Grapefruit Seed Extract is a must-have for your cupboard.”\n\n• “. . . it is ‘Grapefruit’ Seed Extract (abbreviated as GSE or GFSE) that works as a natural antibiotic with anti-viral, anti-bacterial, and anti-fungal properties.”\n\n• Under the heading “Internal Uses”:\n\n− “Fight Colds, Flus, Viruses”\n\n− “Reach for the GSE at the first symptoms of flu or cold.”\n\n− “Traveler’s Diarrhea – As a preventative when traveling in areas with questionable water, mix 1 or 2 drops GSE in each glass of water, or on your toothbrush to disinfect and help prevent Traveler’s diarrhea.”\n\n− “Diarrhea – If you do experience a case of diarrhea, take 15 to 25 drops GSE every 3 to 4 hours in water or juice – no more than 75 drops per day. Or, 2 capsules\u002Ftablets (no more than 6 per day) every 4 hours.”\n\n− “Parasites . . . Use the same amount of GSE as for diarrhea, with possibly increasing to a maximum of 5 doses per day.”\n\n− “There have been anecdotal reports of GSE helping some serious illnesses, such as Chronic Fatigue Syndrome, AIDS, and even Cancer.”\n\n• “There are many more uses for GSE. Once you have successfully used it for something simple, like fighting a cold, you may find yourself reaching for it, regularly, whenever you find a need for its anti-viral, anti-fungal, and anti-bacterial properties.”\n\nCellRenewPRO product:\n\nOn the CellRenewPRO product webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fcollections\u002Fjoint-soft-tissue-support\u002Fproducts\u002Fcellrenew-pro-hydrolyzed-collagen-type-ii):\n\n• “CellRenew PRO provides multi-dimensional nutritional components vital for repairing connective soft tissue (joints, skin, cardiovascular, etc.).”\n\nOn the CellRenewPRO supplement facts and monograph webpage (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-pro-defined):\n\n• “CellRenew Pro is Ultimate Joint Repair”\n\n• “CellRenew PRO provides multi-dimensional nutritional components vital for repairing connective soft tissue (joints, skin, cardiovascular, etc.).”\n\nCellRenewPRO and CellRenewSTS products:\n\nOn the CellRenewPRO (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-pro-defined) and CellRenewSTS (https:\u002F\u002Fstore.appliedhealth.com\u002Fpages\u002Fcellrenew-sts-supplement-facts-and-monograph) supplement facts and monograph webpages:\n\n• “CellRenew contains Hydrolyzed Collagen Type II derived from 100% pure chicken sternal cartilage. As an abundant source of naturally-occurring Hyaluronic Acid and Chondroitin Sulfates, Collagen Type II is easily absorbed to restore joint and cartilage health.”\n\n• “It is an absorbable hydrolyzed collagen type II product . . . that . . . relieves joint discomfort and increases mobility.”\n\n• Under the heading “Research”:\n\n− “Collagen Type II (CCII) [an ingredient in CellRenewPRO and CellRenewSTS] . . . can suppress pro-inflammatory activity to reduce joint discomfort and restore cartilage health. CCII from chicken sternal cartilage was shown to reduce chronic joint inflammation . . .”\n\n− “A three-month study recruited 60 patients with chronic joint inflammation to take CCII or a placebo. Results indicated CCII alleviated swollen and tender joints in the treatment group. Four patients in the treatment group had a complete remission of chronic joint inflammation.”\n\n− “Similarly, a pilot-study recruited female subjects with joint pain to take Hydrolyzed Collagen Type II for 42 days. Subjects reported a significant improvement in joint mobility and decrease in joint pain and stiffness.”\n\n− “CCII is evidenced to be effective among adolescents with chronic joint inflammation. A pilot-study administered CCII to 10 adolescent patients with chronic joint inflammation for 12 weeks. Eight patients experienced a reduction in swollen and tender joints. A similar pilot-study recruited nine adolescents with chronic joint inflammation to take an oral Collagen Type II, finding the supplement . . . reduced joint inflammation.”\n\n− “Chondroitin Sulfate (Component of Collagen Type II) [an ingredient in CellRenewPRO and CellRenewSTS] Naturally found in sternal chicken Collagen Type II, chondroitin sulfate has anti-inflammatory activity that reduces joint swelling, maintains synovial fluid levels, and spacing between the joints. Further, chondroitin sulfate reduces the proliferation of proteins to reduce joint inflammation.”\n\n− “A one-year study recruited 42 patients with knee pain to take chondroitin sulfate or a placebo. Subjects taking chondroitin sulfate had greater joint mobility and less pain, when compared to the placebo group.”\n\n− “A three-month study recruited 110 patients with knee pain to take chondroitin sulfate or a placebo finding supplementation improved knee function, reduced pain, and maintained joint space in the knee.”\n\n− “Researchers suggested chondroitin sulfate and glucosamine could repair and regenerate cartilage . . .”\n\n− “Hyaluronic Acid (Component of Collagen Type II) [an ingredient in CellRenewPRO and CellRenewSTS] . . . Studies have suggested hyaluronic acid has anti-inflammatory activity that suppresses pro-inflammatory and pain mechanisms in the body.”\n\n− “Researchers found that HA inhibited inflammatory cytokine activity in mice with inflamed joints. A similar study reviewed the effect of HA on acute and chronic inflammation in rats, finding HA suppressed inflammatory reactions . . .”\n\nOn the homepage for the https:\u002F\u002Fappliedhealth.com website:\n\n• “How do you help knee pain? . . . CellRenew PRO is Extreme Knee Protection”\n\n• “CellRenew Additional Links . . . CellRenew Collagen Type II and Knee Pain . . . Is Collagen Type II A Cure For Arthritis And Heart Disease . . .”\n\n• In the response to the question “What is CellRenew?”:\n\n− “Unlike other protocols for arthritis symptoms, whether prescription or natural, CellRenew is guaranteed for results.”\n\n− “It contains naturally occurring Hyaluronic Acid and Chondroitin Sulfate. The results of a human clinical trial using this material showed significant improvements in the reduction of joint swelling, tenderness, and pain, as well as successful increases in mobility.”\n\n• In the response to the question “Who is a good candidate to take CellRenew?”:\n\n− “Although studies have shown that many different conditions respond to Collagen Type II, the conditions that have shown the greatest response are rheumatoid arthritis and osteoarthritis. If you have grown weary of traditional protocols that only cover-up symptoms and neglect to address the root cause, then you are an excellent candidate to begin a program of Collagen Type II.”\n\n− “CellRenew is also used as a preventative measure for athletes who . . . are looking for a way to maintain healthy joints prior to the onset of osteoarthritis.”\n\n• In response to the question “What will it do for me?”:\n\n− “Collagen Type II (CTII) [an ingredient in CellRenewPRO and CellRenewSTS] has been suggested to offer significant benefits for some types of arthritis. . . . Rheumatoid arthritis (RA) is the most well known of the autoimmune types of arthritis. In the case of RA, the collagen in the joints is attacked.”\n\n− “Depending on the particular type of arthritis you experience, CTII goes to work in different ways. If you suffer from RA, CTII acts as an oral tolerization agent, instructing the body to stop the immune response to the collagen in the joints. . . . For those suffering from osteoarthritis, CTII provides the critical building blocks that restore a healthy state to the cartilage in the joints.”\n\n− “CellRenew is made from chicken sternal cartilage that contains the highest level of naturally occurring anti-inflammatory proteoglycans (Hyaluronic Acid and Chondroitin Sulfate A) of any other material tested, including shark cartilage. It is important to note that the combination of the proteoglycans and the Collagen Type II proteins . . . provide the building blocks required to rebuild lost cartilage to restore the joint to a normal state.”\n\n• In response to the question “What do the studies show?”:\n\n− “The results of a recent double-blind, placebo-controlled, clinical trial has proved the benefits of Collagen Type II for treating the symptoms of pain and immobility associated with arthritis. . . . report an 89.9% positive response rate, within 45 days, for the participants who consumed at least 2000 mg of Collagen Type II per day.”\n\n− “[R]eported having successfully treated more than 50 patients, starting in 1974, with osteoarthritis, rheumatoid arthritis, psoriasis, and many other ailments. . . .”\n\n− “Of the different types of cartilage tested, the one with the highest level of Collagen Type II, anti-inflammatory proteoglycans (the healing properties) was chicken sternal cartilage. CellRenew is 100% chicken sternal cartilage.”\n\n• In response to the question “What else is it good for?”:\n\n− “Besides the better-known associations with osteoarthritis and rheumatoid arthritis, it has also been suggested that Collagen Type II might benefit heart disease, psoriasis, progressive myopia, and some other autoimmune diseases.”\n\n• In response to the question “How long before I improve?”:\n\n− “Although some people have noticed an improvement with their symptoms after only a week or two of starting a CellRenew program, many take between 4 and 6 weeks. . . . some forms of arthritis symptoms tend to respond faster – on average – than other forms. For instance, we do know that rheumatoid arthritis sufferers have a tendency to respond faster . . .”\n\nUnder the heading “CellRenew Customer Stories” on the homepage for the https:\u002F\u002Fappliedhealth.com website:\n\n• “‘I have been taking CellRenew since May of 2003. . . . This product has kept my arthritis at bay. . . .’”\n\n• “‘[T]hank you for the dramatic results I have experienced in the first three weeks of taking CellRenew. For the past twenty years, I have been living with severe lower back pain. I was diagnosed with a degenerative disc disorder in the L2, L3, and L4 vertebrae. . . . CellRenew has improved my quality of life one thousand percent.’”\n\n• “‘Fourteen months ago – diagnosed with scoliosis, osteoarthritis of the spine and degenerative disc disease – my active life was gone . . . I was in excruciating pain most of the time. . . . On the xray [sic], my spine looked like a rock pile. . . . Enter CellRenew, and within one month, the improvement was incredible. That was four months ago. . . . I have my life back. I know that CellRenew works!’”\n\n• “‘I wanted to tell you all about how thrilled I am with CellRenew. I have been taking CellRenew for just over a year now. I have not had a single ache or pain in at least 10 months. I have experienced no side effects, except for one good side effect. I have changed my eyeglass prescription, twice! Both times were for the better! My eyesight is improving. . . .’”\n\nUnder the heading “In the beginning…” on the homepage for the https:\u002F\u002Fappliedhealth.com website:\n\n• “Bill Evans, President, Applied Health . . . my lifestyle was finally catching up to me . . . due to rapidly progressing arthritis. . . . Instead of a future filled with the pursuit of my favorite activities, and dreams of conquering the Bucket List, I only saw the prospect of surgeries, painkillers, and physical therapy. I decided there had to be a better way than knee replacement and a cocktail of medications. A year later, in 1997, we started Applied Health and introduced our first Collagen-based, joint support product using hydrolyzed collagen type II . . . We called it CellRenew, and over 20 years later, we still have devoted users . . . [ellipsis in original] myself among them.”\n\nOn the “CellRenew Hydrolyzed Collagen Type II Technical Outline” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fcellrenew-technical-outline\u002F):\n\n• Under the heading “Key Product Highlights\u002FBullets”:\n\n− “CellRenew is so effective that the raw material has been awarded two United States Patents . . . for the treatment of connective tissue disorder, osteoarthritis, degenerative joint disease, joint defects, vascular disease, and cartilage injuries . . .”\n\n− “May help support proper inflammatory function due to its chondroitin sulfate content . . .”\n\n− “May possibly support proper wound healing due to its potent hyaluronic acid content . . .”\n\n• Under the heading “Studies and Mechanisms of action”:\n\n− “CellRenew and its components can have a powerful impact on joints and conditions associated with abnormal joint function. One study [footnote omitted] published in 2000 entitled ‘Role of collagen hydrolysate in bone and joint disease’, reviews how collagen can be a powerful tool in helping with osteoarthritis and even osteoporosis. . . . Mechanism of action: The components of CellRenew . . . lower the chance for deterioration.”\n\n− “‘[H]yaluronan preparations have been shown to decrease pain and increase function in patients with osteoarthritis of the knee.’ Mechanism of action: Hyaluronic Acid seems to work through several mechanisms of action including restoration of more normal synovial fluid with improved viscoelasticity, effects on cartilage biosynthesis and degradation, anti-inflammatory effects, and direct analgesic effects.”\n\n• Under the heading “Patent Claims”:\n\n− “2. A method for treating an individual with a connective tissue disorder . . .”\n\n− “3. The method of claim 2, wherein said connective tissue disorder is selected from the group consisting of degenerative joint diseases, joint defects, osteoarthritis, polychondritis, vascular disease, cartilage injuries, progressive myopia and Menier’s [sic] disease.”\n\nOn the “Effects of Collagen Type II For Subjective Pain Relief” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fhydrolyzed-collagen-clinical-trial\u002F), which contains a hyperlink to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\n\n• The following quote appears after a summary of a study on the effects of Collagen Type II (an ingredient in CellRenewPRO and CellRenewSTS) on the course of pain syndromes, including rheumatoid arthritic pain, osteoarthritis joint pain, post surgical joint pain, post traumatic pain, fibrositis, gouty arthritis, lumbosacral pain with\u002Fwithout radicular pain, and cervical spine pain with\u002Fwithout radicular pain: “‘The results were overwhelmingly positive for pain relief and the side benefits were remarkable! This product has changed my life significantly.’”\n\nOn the “Is Collagen Type II A Cure For Arthritis And Heart Disease?” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fcollagen-type-ii-cure-arthritis-heart-disease\u002F), which hyperlinks to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\n\n• Under the heading “Collagen Type II [an ingredient in CellRenewPRO and CellRenewSTS] and Arthritis”:\n\n− “. . . 50 million Americans suffer from some form of arthritis, either rheumatoid or osteoarthritis, as well as a variety of other arthritic conditions. . . . Could it be that one nutritional medicine called collagen type II can ameliorate both disorders in an effective way?”\n\n− “It may turn out that the natural components of cartilage hold the greatest promise of ameliorating both arthritis and heart disease.”\n\n− “If collagen type II is derived from chicken sternal cartilage, from chicks six to eight weeks old, it contains the greatest number of anti-inflammatory and joint supporting proteoglycans. These proteoglycans include glucosamine sulfate which has over 30 years of double-blind, placebo-controlled studies indicating that it actually helps to rebuild the cartilage in arthritis joints.”\n\n− “[I]t contains a high concentration of chondroitin sulfate A, which is a powerful anti-inflammatory . . .”\n\n− “[C]ollagen type II also contains a powerful, newly discovered antioxidant proteoglycan called cartilage matrix glycoprotein (CMGP), which can help reduce the oxidative damage to the joint.”\n\n− “When people suffer from arthritis, there is a selective destruction of collagen type II in the joint cartilage itself. Scientists know that this particular component of cartilage is being attacked by white blood cells and somehow this activates the immune system in the rheumatoid arthritic patient to develop antibodies to collagen type II. This then sets up an immune response to all of the cartilage that is degenerating in the body. Thus, both wrists hurt, both knees hurt, the hips, the back, etc.”\n\n− “The question now becomes how does collagen type II turn off the immune system in the rheumatoid arthritic. The answer is that collagen type II’s effectiveness is accomplished through ‘oral tolerance.’”\n\n− “. . . investigate the side effects of chicken sternal collagen type II being fed to arthritic rats. . . . By the second or third months the rats no longer displayed any symptoms of arthritis. There was a profound amelioration of the disease.”\n\n− “. . . studied ten people with severe rheumatoid arthritis. They eliminated the standard therapies such as NSAIDS and methotrexate and fed the patients pure collagen type II derived from chicken sternal cartilage. At the end of the second month, six of the ten patients showed substantial improvement and one showed a complete regression of the disease that lasted 26 months with no side effects.”\n\n− “. . . conducted a phase II trial on 59 patients with, again, severe active rheumatoid arthritis. . . . What is interesting is that those who were off all drugs and taking collagen type II showed very significant stabilization and improvement, while those on placebos continued to deteriorate. In fact, four collagen type II patients showed a complete resolution of the disease . . .”\n\n− “We see that oral ingestion of collagen type II may well prove to be the most effective natural means of arthritis management regardless of the form of the disease.”\n\n− “. . . this is precisely why it works in osteoarthritis . . . collagen type II has such a high concentration of glucosamine and chondroitin . . .”\n\n− “In lieu [sic] of the fact that there are no side effects with collagen type II, this would seem to be the product of choice when suffering from any form of arthritic condition.”\n\n− “. . . collagen II components are truly chondro-protective agents because they . . . reprogram destructive chondrocytes and cytokines, reducing inflammation . . . protect the surface of the cartilage from oxidative damage . . . act as a powerful anti-inflammatory and pain modulator.”\n\n• Under the heading “Collagen Type II [an ingredient in CellRenewPRO and CellRenewSTS] and Heart Disease”:\n\n− “Medicines such as aspirin and NSAIDS, as well as natural therapeutics such as fish liver oil or antiarthritic herbs, cannot compete with the overall biochemical power of collagen type II.”\n\n− “. . . collagen type II is 14.2 percent chondroitin sulfate A. . . . Chondroitin sulfate A (CSA) has a powerful antithrombogenic or anticoagulant affect, which, in essence, prevents blood clots and has been shown to reduce the incidence of stroke.”\n\n− “. . . CSA literally reduced the cholesterol and other lipids in the blood and actually ‘cleared’ cholesterol from the lining of arteries, including the aorta.”\n\n− “This indicates a 600 percent reduction in the incidence of fatal heart attacks simply by taking oral CSA on a daily basis . . .”\n\n− “Collagen type II has also found some support in the research for the amelioration of autoimmune disease caused by breast implant poisoning, as well as amelioration of Menier’s [sic] disease and progressive myopia.”\n\nOn the “The Village of Long Life” webpage (https:\u002F\u002Fappliedhealth.com\u002Fcellrenew-collagen-type-ii\u002Fhyaluronic-acid-abc-news\u002F), which hyperlinks to the online storefront where the CellRenewPRO and CellRenewSTS products can be purchased:\n\n• “. . . hyaluronic acid [a component of the Hydrolyzed Collagen II ingredient in the CellRenewPRO and CellRenewSTS products] has been used for years in eye surgery as a shock absorber to protect the retina, and has been proven effective in lubricating arthritic joints.”\n\n• “But HA has been shown to have wound-healing and tissue-reconstruction applications . . .”\n\nOn the “Collagen Type II for Arthritis Pain Relief” blog post (https:\u002F\u002Fappliedhealth.com\u002Fcollagen-type-ii-for-arthritis-pain-relief\u002F):\n\n• “Collagen Type II [an ingredient in the CellRenewPRO and CellRenewSTS products] for Arthritis Pain Relief”\n\n• “Does Collagen Type II relieve osteoarthritis? Research says, yes.”\n\n• “Collagen type II (CTII) is an effective source for alleviating joint stiffness and increasing mobility. Several studies have found CTII reduces joint pain in rheumatoid arthritis, but a new study . . . found that it is also an effective treatment for osteoarthritis.”\n\n• “Researchers recruited 52 subjects with osteoarthritis in the knees to take CTII or a glucosamine\u002Fchondroitin combination for 90 days. . . . Overall, CTII reduced joint pain by 40%.”\n\n• “How does collagen type II alleviate joint pain? CTII is the primary form of collagen naturally found in joint cartilage. The body needs CTII to rebuild connective tissue. Supplementing with a superior form of collagen can help reduce inflammation and the breakdown of collagen in the body. For the best absorption, choose a hydrolyzed collagen type II to restore joint health.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. § 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. §§ 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. § 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour Applied Health Solutions brand products B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, and the NutriBiotic brand products Grapefruit Seed Extract CapsulesPlus and Grapefruit Seed Extract Liquid Concentrate are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes. Accordingly, the B Complex, Daily Detox, CellRenewPRO, CellRenewSTS, Grapefruit Seed Extract CapsulesPlus, and Grapefruit Seed Extract Liquid Concentrate products fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. § 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. § 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour written response should be sent to the following address: 6th Ave and Kipling St, DFC Bldg. 20, PO Box 25087, Denver, Colorado, 80225-0087, to the attention of Compliance Officer Carrie Jolly or by email to carrie.jolly@fda.hhs.gov. If you need additional information or have questions concerning any products distributed through your website, please contact CO Jolly at carrie.jolly@fda.hhs.gov or (303) 236-9656.\n\nSincerely,\n\n\u002FS\u002F\n\nE. Mark Harris\n\nDenver District Director & Program Division Director\n\nOffice of Human and Animal Food Operations −\n\nDivision IV West","Applied Health Solutions, Inc.","applied-health-solutions-inc-616778-10222021","2026-08-18T06:42:29.262718+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapplied-health-solutions-inc-616778-10222021","2026-10-26T08:07:56.864908+00:00","Warning Letter","Issued","2022-02-01","616778","Drugs","William Evans","2026-08-20T02:12:48.529+00:00","VIA UPS","2021-10-22",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":48,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":49,"medical_device_id":19,"response_letter_date":19},2166,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2023-03-14T13:20:00Z\">03\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-02T05:00:00Z\">03\u002F02\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felectrx-and-health-solutions-llc-614251-03022023\">ElectRx and Health Solutions, LLC\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Finished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>ElectRx and Health Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cdiv>\n\u003Cp>FROM: The United States Food and Drug Administration\u003C\u002Fp>\n\n\u003Cp>RE: Causing the Introduction of Unapproved and Misbranded Drugs into Interstate Commerce\u003C\u002Fp>\n\n\u003Cp>DATE: March 2, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The United States (U.S.) Food and Drug Administration (FDA) has observed that ElectRx and Health Solutions, LLC (“ElectRx”) causes the introduction of unapproved new drugs and misbranded drugs into interstate commerce in violation of sections 301(a), 301(d), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 331(a), 331(d), and 355(a)].\u003C\u002Fp>\n\n\u003Cp>There are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that ElectRx cease causing the introduction of unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from potential harm.\u003C\u002Fp>\n\n\u003Cp>ElectRx contracts with public and private sector employers throughout the U.S. to provide select prescription drugs to employees. ElectRx acts as a broker between foreign pharmacies and the employee-sponsored health insurance plans to provide enrolled employees with prescription drugs. ElectRx accepts the employee’s U.S. prescription and facilitates the dispensing of the prescription drug by a foreign pharmacy. The foreign pharmacy then ships the drug directly to the employee in the U.S. Invoices for prescription drugs purchased through ElectRx state, “You may have noticed that the medication which has been shipped to you is different in name or presentation to that which you may have received in the past. IF YOU HAVE ORDERED A BRANDED DRUG the name may appear different to the one you are used to. The reason for this is that you have been supplied internationally branded product and for various reasons drug companies market their products under different names and packaging in different countries.” Additionally, several of ElectRx’s formularies include the statement, “Please note that the medications ordered from the ElectRx formulary are sourced internationally, and may be marketed with a different name or a different strength to medications in the USA.” These statements demonstrate that ElectRx has designed its business to operate in a manner that substitutes the FDA-approved drugs prescribed by the U.S. healthcare provider with unapproved drugs. This distribution scheme is particularly concerning, as employees are likely inclined to trust that they will receive safe and effective drugs through their employer’s “insurance” plan and may not question their legitimacy.\u003C\u002Fp>\n\n\u003Cp>The substitution of FDA-approved prescription drugs with unapproved drugs poses significant health risks to U.S. consumers. For example, ElectRx offers certain drugs on its formularies for which the FDA-approved version is subject to a Risk Evaluation and Mitigation Strategy (REMS)\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> program, has a narrow therapeutic index (NTI)\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, is a controlled substance, and\u002For is indicated to treat serious conditions such as HIV, cancer, or hepatitis. ElectRx also offers maintenance medications that are indicated for conditions such as high blood pressure, high cholesterol, and acid reflux. Substituting an unapproved drug for the FDA-approved drug prescribed by a patient’s healthcare practitioner can negatively affect patient outcomes because the healthcare practitioner may unknowingly make subsequent treatment decisions based on the patient's response to the unapproved drug. This can also cause potentially dangerous drug interactions with the patient’s other medications. This is of particular concern for drugs subject to REMS programs and NTI drugs. Moreover, the substitution of FDA-approved prescription drugs with unapproved versions that may have substantially different risk profiles can pose serious health risks to consumers, especially in vulnerable patient populations that suffer from serious conditions.\u003C\u002Fp>\n\n\u003Cp>Prescription medicines that are approved for use in the United States have been reviewed by FDA for safety, effectiveness, and quality and are subject to FDA-regulated manufacturing controls and FDA inspections of manufacturing facilities. Unapproved foreign drugs circumvent these safeguards, which are designed to protect patients. Unapproved drugs do not have the same assurance of safety and efficacy as drugs subject to FDA oversight and may be subpotent, superpotent, or adulterated with unknown active ingredients. Treatment with drugs that may be subpotent, superpotent, or adulterated can lead to drug resistance and\u002For therapeutic failures, and jeopardize the effectiveness of alternative drug therapies on patient outcomes.\u003C\u002Fp>\n\n\u003Cp>FDA has also established processes to recall unsafe, substandard, and poor-quality drugs within the legitimate U.S. drug supply chain. No such safeguards exist for unapproved drugs illegally distributed in the U.S. from foreign sources such as those provided through ElectRx. In addition, the unapproved versions of FDA-approved drugs offered by ElectRx may have different trade names and\u002For strengths in their labeling than their FDA-approved counterparts. Such differences can cause patient confusion and lead to medication errors.\u003C\u002Fp>\n\n\u003Cp>Examples of drugs offered on ElectRx’s formularies and a general description of their respective indications are depicted in the table below. These include drugs that are for vulnerable patient populations with serious medical conditions. This is not an exhaustive list of the drugs offered on ElectRx formularies.\u003C\u002Fp>\n\n\u003Ctable>\n\t\u003Ctbody>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Advair Diskus (asthma, COPD)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Invirase (HIV)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Afinitor (cancer)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Opsumit (pulmonary arterial hypertension)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Astagraf XL (organ rejection)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Tasigna (cancer)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Descovy (HIV)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Truvada (HIV)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Epivir‐HBV (hepatitis)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Vemlidy (hepatitis)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Gilotrif (cancer)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Vimpat (epilepsy)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\t\u003Ctr>\n\t\t\t\u003Ctd>Inlyta (cancer)\u003C\u002Ftd>\n\t\t\t\u003Ctd>Zortress (organ rejection)\u003C\u002Ftd>\n\t\t\u003C\u002Ftr>\n\t\u003C\u002Ftbody>\n\u003C\u002Ftable>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As described above, ElectRx causes the introduction of unapproved new drugs from foreign sources into interstate commerce in the United States in violation of the FD&amp;C Act by substituting the FDA-approved drugs prescribed by a patient’s physician with unapproved drugs sourced from foreign pharmacies. Because these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For affect the structure or function of the body, these products are drugs within the meaning of section 201(g)(1) of the FD&amp;C Act [21 U.S.C. § 321(g)(1)]. These products are also new drugs as defined by section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions that do not apply here, new drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act [21 U.S.C. § 355(a)]. No FDA-approved applications pursuant to section 505 of the FD&amp;C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act [21 U.S.C. §§ 331(d) and 355(a)].\u003C\u002Fp>\n\n\u003Cp>For example, one of the drugs provided via ElectRx is tacrolimus extended-release capsules, manufactured by Astellas and marketed as “Advagraf.” While there are FDA-approved versions of tacrolimus extended-release capsules on the market in the U.S., including “Astagraf XL” manufactured by Astellas, there are no approved drug applications pursuant to section 505 of the FD&amp;C Act in effect for the “Advagraf” provided by ElectRx. Extended-release capsules of tacrolimus administered orally are NTI drugs. FDA-approved tacrolimus extended-release capsules are indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients who can swallow capsules intact. FDA-approved tacrolimus extended-release capsules bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses an increased risk for developing serious infections and malignancies with tacrolimus or other immunosuppressants that may lead to hospitalization or death, and increased mortality in female liver transplant patients.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drugs:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Prescription drugs, as defined in section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)] include those that, because of their toxicity or other potentiality for harmful effect, and\u002For the method of their use, and\u002For the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&amp;C Act, can be used safely only at the direction, and under the supervision, of a licensed practitioner. Because ElectRx advises consumers that their U.S. prescriptions are being filled with less expensive, foreign drugs, ElectRx concedes that these drugs are prescription drugs.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the FD&amp;C Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). The drugs offered by ElectRx are prescription drugs intended to treat conditions that are not amenable to self-diagnosis and treatment by persons who are not medical practitioners. Therefore, adequate directions for use cannot be written for these drugs, and they must qualify for one of the exemptions to section 502(f)(1) to avoid being misbranded. The exemption to section 502(f)(1) found at 21 CFR § 201.100 does not apply to unapproved new drugs because that exemption requires that such drugs bear “the labeling authorized by the approved new drug application.” In addition, because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&amp;C Act. Because none of the exemptions to section 502(f)(1) apply, these drugs are misbranded under section 502(f)(1).\u003C\u002Fp>\n\n\u003Cp>By causing these products to be shipped to U.S. consumers, ElectRx is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>FDA is sending this Warning Letter to ElectRx because of the risks posed by its conduct in causing the importation of unapproved new drugs and misbranded drugs to U.S. consumers. FDA’s regulation and oversight of the drug approval process protects consumers by requiring rigorous scientific standards for new drug approval, labeling review for accuracy and completeness, and manufacturing procedures and testing performed under closely controlled conditions at FDA-registered and inspected facilities.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to identify all the ways in which your activities might be in violation of U.S. law. You should promptly cease causing the distribution of unapproved new drugs and misbranded drugs to U.S. consumers and correct any other violations of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within 15 working days of receipt of this letter describing the specific steps you have taken or will take to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action, including but not limited to, seizure, injunction, and\u002For temporary restraining order without further notice. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration within 15 working days. Please direct your response, and any inquiries concerning this letter, to FDA at CDERDrugSupplyChainIntegrity@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nS. Leigh Verbois, Ph.D.\u003Cbr>\nDirector, Office of Drug Security, Integrity, and Response\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> A REMS is a drug safety program that the U.S. Food and Drug Administration (FDA) can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. REMS are designed to reinforce medication use behaviors and actions that support the safe use of that medication.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Narrow therapeutic index (NTI) drugs are drugs where small differences in dose or blood concentration may lead to serious therapeutic failures and\u002For adverse drug reactions that are life-threatening or result in persistent or significant disability or incapacity.\u003C\u002Fp>\n\u003C\u002Fdiv>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nElectRx and Health Solutions, LLC\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nFROM: The United States Food and Drug Administration\n\nRE: Causing the Introduction of Unapproved and Misbranded Drugs into Interstate Commerce\n\nDATE: March 2, 2023\n\nWARNING LETTER\n\nThe United States (U.S.) Food and Drug Administration (FDA) has observed that ElectRx and Health Solutions, LLC (“ElectRx”) causes the introduction of unapproved new drugs and misbranded drugs into interstate commerce in violation of sections 301(a), 301(d), and 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 331(a), 331(d), and 355(a)].\n\nThere are inherent risks to consumers who purchase unapproved new drugs and misbranded drugs. Unapproved new drugs do not carry the same assurances of safety and effectiveness as those drugs subject to FDA oversight. Drugs that have circumvented regulatory safeguards may be contaminated, counterfeit, contain varying amounts of active ingredients, or contain different ingredients altogether. Accordingly, FDA requests that ElectRx cease causing the introduction of unapproved and misbranded drugs for sale to U.S. consumers. This is critical to shielding the American public from potential harm.\n\nElectRx contracts with public and private sector employers throughout the U.S. to provide select prescription drugs to employees. ElectRx acts as a broker between foreign pharmacies and the employee-sponsored health insurance plans to provide enrolled employees with prescription drugs. ElectRx accepts the employee’s U.S. prescription and facilitates the dispensing of the prescription drug by a foreign pharmacy. The foreign pharmacy then ships the drug directly to the employee in the U.S. Invoices for prescription drugs purchased through ElectRx state, “You may have noticed that the medication which has been shipped to you is different in name or presentation to that which you may have received in the past. IF YOU HAVE ORDERED A BRANDED DRUG the name may appear different to the one you are used to. The reason for this is that you have been supplied internationally branded product and for various reasons drug companies market their products under different names and packaging in different countries.” Additionally, several of ElectRx’s formularies include the statement, “Please note that the medications ordered from the ElectRx formulary are sourced internationally, and may be marketed with a different name or a different strength to medications in the USA.” These statements demonstrate that ElectRx has designed its business to operate in a manner that substitutes the FDA-approved drugs prescribed by the U.S. healthcare provider with unapproved drugs. This distribution scheme is particularly concerning, as employees are likely inclined to trust that they will receive safe and effective drugs through their employer’s “insurance” plan and may not question their legitimacy.\n\nThe substitution of FDA-approved prescription drugs with unapproved drugs poses significant health risks to U.S. consumers. For example, ElectRx offers certain drugs on its formularies for which the FDA-approved version is subject to a Risk Evaluation and Mitigation Strategy (REMS)1 program, has a narrow therapeutic index (NTI)2, is a controlled substance, and\u002For is indicated to treat serious conditions such as HIV, cancer, or hepatitis. ElectRx also offers maintenance medications that are indicated for conditions such as high blood pressure, high cholesterol, and acid reflux. Substituting an unapproved drug for the FDA-approved drug prescribed by a patient’s healthcare practitioner can negatively affect patient outcomes because the healthcare practitioner may unknowingly make subsequent treatment decisions based on the patient's response to the unapproved drug. This can also cause potentially dangerous drug interactions with the patient’s other medications. This is of particular concern for drugs subject to REMS programs and NTI drugs. Moreover, the substitution of FDA-approved prescription drugs with unapproved versions that may have substantially different risk profiles can pose serious health risks to consumers, especially in vulnerable patient populations that suffer from serious conditions.\n\nPrescription medicines that are approved for use in the United States have been reviewed by FDA for safety, effectiveness, and quality and are subject to FDA-regulated manufacturing controls and FDA inspections of manufacturing facilities. Unapproved foreign drugs circumvent these safeguards, which are designed to protect patients. Unapproved drugs do not have the same assurance of safety and efficacy as drugs subject to FDA oversight and may be subpotent, superpotent, or adulterated with unknown active ingredients. Treatment with drugs that may be subpotent, superpotent, or adulterated can lead to drug resistance and\u002For therapeutic failures, and jeopardize the effectiveness of alternative drug therapies on patient outcomes.\n\nFDA has also established processes to recall unsafe, substandard, and poor-quality drugs within the legitimate U.S. drug supply chain. No such safeguards exist for unapproved drugs illegally distributed in the U.S. from foreign sources such as those provided through ElectRx. In addition, the unapproved versions of FDA-approved drugs offered by ElectRx may have different trade names and\u002For strengths in their labeling than their FDA-approved counterparts. Such differences can cause patient confusion and lead to medication errors.\n\nExamples of drugs offered on ElectRx’s formularies and a general description of their respective indications are depicted in the table below. These include drugs that are for vulnerable patient populations with serious medical conditions. This is not an exhaustive list of the drugs offered on ElectRx formularies.\n\nAdvair Diskus (asthma, COPD)\nInvirase (HIV)\n\nAfinitor (cancer)\nOpsumit (pulmonary arterial hypertension)\n\nAstagraf XL (organ rejection)\nTasigna (cancer)\n\nDescovy (HIV)\nTruvada (HIV)\n\nEpivir‐HBV (hepatitis)\nVemlidy (hepatitis)\n\nGilotrif (cancer)\nVimpat (epilepsy)\n\nInlyta (cancer)\nZortress (organ rejection)\n\nUnapproved New Drugs:\n\nAs described above, ElectRx causes the introduction of unapproved new drugs from foreign sources into interstate commerce in the United States in violation of the FD&C Act by substituting the FDA-approved drugs prescribed by a patient’s physician with unapproved drugs sourced from foreign pharmacies. Because these products are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For affect the structure or function of the body, these products are drugs within the meaning of section 201(g)(1) of the FD&C Act [21 U.S.C. § 321(g)(1)]. These products are also new drugs as defined by section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses. With certain exceptions that do not apply here, new drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act [21 U.S.C. § 355(a)]. No FDA-approved applications pursuant to section 505 of the FD&C Act [21 U.S.C. § 355] are in effect for these products. Accordingly, their introduction or delivery for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act [21 U.S.C. §§ 331(d) and 355(a)].\n\nFor example, one of the drugs provided via ElectRx is tacrolimus extended-release capsules, manufactured by Astellas and marketed as “Advagraf.” While there are FDA-approved versions of tacrolimus extended-release capsules on the market in the U.S., including “Astagraf XL” manufactured by Astellas, there are no approved drug applications pursuant to section 505 of the FD&C Act in effect for the “Advagraf” provided by ElectRx. Extended-release capsules of tacrolimus administered orally are NTI drugs. FDA-approved tacrolimus extended-release capsules are indicated for the prophylaxis of organ rejection in kidney transplant patients in combination with other immunosuppressants in adult and pediatric patients who can swallow capsules intact. FDA-approved tacrolimus extended-release capsules bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious or even life-threatening adverse effects. The boxed warning addresses an increased risk for developing serious infections and malignancies with tacrolimus or other immunosuppressants that may lead to hospitalization or death, and increased mortality in female liver transplant patients.\n\nMisbranded Drugs:\n\nPrescription drugs, as defined in section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)] include those that, because of their toxicity or other potentiality for harmful effect, and\u002For the method of their use, and\u002For the collateral measures necessary for their use, are not safe for use except under supervision of a practitioner licensed by law to administer them. Prescription drugs, as defined in section 503(b)(1)(A) of the FD&C Act, can be used safely only at the direction, and under the supervision, of a licensed practitioner. Because ElectRx advises consumers that their U.S. prescriptions are being filled with less expensive, foreign drugs, ElectRx concedes that these drugs are prescription drugs.\n\nA drug is misbranded under section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). The drugs offered by ElectRx are prescription drugs intended to treat conditions that are not amenable to self-diagnosis and treatment by persons who are not medical practitioners. Therefore, adequate directions for use cannot be written for these drugs, and they must qualify for one of the exemptions to section 502(f)(1) to avoid being misbranded. The exemption to section 502(f)(1) found at 21 CFR § 201.100 does not apply to unapproved new drugs because that exemption requires that such drugs bear “the labeling authorized by the approved new drug application.” In addition, because these drugs are not approved in the U.S., they are also not exempt under 21 CFR 201.115(a) from the requirements of section 502(f)(1) of the FD&C Act. Because none of the exemptions to section 502(f)(1) apply, these drugs are misbranded under section 502(f)(1).\n\nBy causing these products to be shipped to U.S. consumers, ElectRx is causing the introduction of misbranded drugs into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nFDA is sending this Warning Letter to ElectRx because of the risks posed by its conduct in causing the importation of unapproved new drugs and misbranded drugs to U.S. consumers. FDA’s regulation and oversight of the drug approval process protects consumers by requiring rigorous scientific standards for new drug approval, labeling review for accuracy and completeness, and manufacturing procedures and testing performed under closely controlled conditions at FDA-registered and inspected facilities.\n\nThis letter is not intended to identify all the ways in which your activities might be in violation of U.S. law. You should promptly cease causing the distribution of unapproved new drugs and misbranded drugs to U.S. consumers and correct any other violations of the FD&C Act.\n\nPlease notify this office in writing within 15 working days of receipt of this letter describing the specific steps you have taken or will take to address any violations and to prevent their recurrence. Include an explanation of each step being taken to remedy and prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately address this matter may result in legal action, including but not limited to, seizure, injunction, and\u002For temporary restraining order without further notice. If the corrective action(s) cannot be completed within 15 working days, state the reason for the delay and the time within which the corrections will be completed. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration within 15 working days. Please direct your response, and any inquiries concerning this letter, to FDA at CDERDrugSupplyChainIntegrity@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nS. Leigh Verbois, Ph.D.\n\nDirector, Office of Drug Security, Integrity, and Response\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\n_____________________\n\n1 A REMS is a drug safety program that the U.S. Food and Drug Administration (FDA) can require for certain medications with serious safety concerns to help ensure the benefits of the medication outweigh its risks. REMS are designed to reinforce medication use behaviors and actions that support the safe use of that medication.\n\n2 Narrow therapeutic index (NTI) drugs are drugs where small differences in dose or blood concentration may lead to serious therapeutic failures and\u002For adverse drug reactions that are life-threatening or result in persistent or significant disability or incapacity.","ElectRx and Health Solutions, LLC","electrx-and-health-solutions-llc-614251-03022023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Felectrx-and-health-solutions-llc-614251-03022023","2026-10-26T08:08:34.115705+00:00","2023-03-14","614251","2026-08-20T01:12:06.472+00:00","2023-03-02",{"id":51,"raw":52,"subject":57,"body_html":58,"body_text":59,"firm_name":60,"letter_id":61,"created_at":62,"fei_number":19,"letter_url":63,"updated_at":64,"action_type":22,"case_status":23,"posted_date":65,"marcs_cms_no":66,"product_type":67,"closeout_date":19,"issuing_office":56,"recipient_name":68,"body_fetched_at":69,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":71,"medical_device_id":19,"response_letter_date":19},31,[53,54,55,56,57,13,13,13],"\u003Ctime datetime=\"2026-07-14T04:00:00Z\">07\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-12T04:00:00Z\">06\u002F12\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnihon-kohden-digital-health-solutions-llc-727803-06122026\">Nihon Kohden Digital Health Solutions, LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Medical Device\u002FAdulterated\u002FMisbranded\u002FLacks PMA and\u002For 510(k)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Harsh Dharwad\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nihon Kohden Digital Health Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14 Bunsen\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irvine\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92618\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6), (b)(7)(C)\"> (b)(6), (b)(7)(C)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS #727803\u003C\u002Fp>\u003Cp>June 12, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Dharwad:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Irvine, CA from February 23, 2026 through February 24, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Next Generation NetKonnect software device, which is a Patient Physiological Monitor device with Arrhythmia detector and alarm (including ST-segment measurement and alarm). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that your Next Generation NetKonnect (NGNK) software device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)(1)(i)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and respond as appropriate.\u003C\u002Fp>\u003Cp>Specifically, your firm’s Next Generation NetKonnect software devices are class II devices regulated under 21 CFR 870.1025 - Arrhythmia detector and alarm (including ST-segment measurement and alarm). Your device was most recently cleared as K220989 on July 29, 2022. On October 22, 2022, you implemented a software change to the device which included the ability to enable a Silence Alarms function. This introduced a device functionality that was not included in the originally cleared device. You completed a Regulatory Assessment for the modification in which you determined it would not significantly affect the safety and efficacy of the device, and that a Letter-to-File was appropriate. At decision point B2 of the assessment, “Is it a control mechanism, operating principles, or energy type change?” you selected “No.” You did not submit a premarket notification for this modification.\u003C\u002Fp>\u003Cp>However, we disagree with this assessment because adding the Silence Alarms function is a change to a control mechanism of the device and we believe that “Yes” should have been selected, leading to “New 510(k).” The addition of a Silence Alarms function is a change to a control mechanism because it modifies the manner in which the user controls the device, which could result in the alarms not operating as the user intends. This change may result in missed alarms for life-threatening conditions that require immediate attention, leading to patient harm such as serious injury and\u002For death. As such, the modification of the device is a change or modification in the device that could significantly affect its safety or effectiveness and requires submission of a 510(k) under 21 CFR 807.81(a)(3)(i).\u003C\u002Fp>\u003Cp>Additionally, the evidence indicates that you are distributing the NGNK software device with an unauthorized intended use that is different from that cleared under K220989. Namely, the labeling of your device indicates that the NGNK device is now intended to have “device-agnostic compatibility.” During the inspection, your firm’s management explained that “device-agnostic” describes NGNK’s ability to 1) run on any brand of commercial off-the-shelf computer and 2) support input from non-Nihon Kohden devices. However, your device was cleared under K220989 to support inputs from only other Nihon Kohden devices, and not from any device from other manufacturers. Therefore, “device-agnostic compatibility” is beyond the scope of the intended use that was cleared for the Next Generation NetKonnect. This change may introduce patient risks because of the use of additional input devices that have not been validated for compatibility with the NGNK software. Inadequate interoperability can result in incorrect vital sign measurements or loss of expected monitoring, which may result in delay of diagnosis or misdiagnosis. This is a major change or modification in the intended use of the device and requires submission of a 510(k) under 21 CFR 807.81(a)(3)(ii).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727803” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>CDR Cesar A. Perez, PhD, USPHS\u003Cbr>Acting Deputy Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Mr. Arthur E. Webb, Director of Software Quality and Regulatory Affairs, art_webb@nihonkohden.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nHarsh Dharwad\n\nRecipient Title\n\nPresident and Chief Executive Officer\n\nNihon Kohden Digital Health Solutions, LLC\n\n14 Bunsen\n\nIrvine, CA 92618\n\nUnited States\n\n(b)(6), (b)(7)(C)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS #727803\nJune 12, 2026\nDear Mr. Dharwad:\nDuring an inspection of your firm located in Irvine, CA from February 23, 2026 through February 24, 2026, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Next Generation NetKonnect software device, which is a Patient Physiological Monitor device with Arrhythmia detector and alarm (including ST-segment measurement and alarm). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nUnapproved Device Violation(s)\nOur inspection revealed that your Next Generation NetKonnect (NGNK) software device is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)(1)(i)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the devices is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and respond as appropriate.\nSpecifically, your firm’s Next Generation NetKonnect software devices are class II devices regulated under 21 CFR 870.1025 - Arrhythmia detector and alarm (including ST-segment measurement and alarm). Your device was most recently cleared as K220989 on July 29, 2022. On October 22, 2022, you implemented a software change to the device which included the ability to enable a Silence Alarms function. This introduced a device functionality that was not included in the originally cleared device. You completed a Regulatory Assessment for the modification in which you determined it would not significantly affect the safety and efficacy of the device, and that a Letter-to-File was appropriate. At decision point B2 of the assessment, “Is it a control mechanism, operating principles, or energy type change?” you selected “No.” You did not submit a premarket notification for this modification.\nHowever, we disagree with this assessment because adding the Silence Alarms function is a change to a control mechanism of the device and we believe that “Yes” should have been selected, leading to “New 510(k).” The addition of a Silence Alarms function is a change to a control mechanism because it modifies the manner in which the user controls the device, which could result in the alarms not operating as the user intends. This change may result in missed alarms for life-threatening conditions that require immediate attention, leading to patient harm such as serious injury and\u002For death. As such, the modification of the device is a change or modification in the device that could significantly affect its safety or effectiveness and requires submission of a 510(k) under 21 CFR 807.81(a)(3)(i).\nAdditionally, the evidence indicates that you are distributing the NGNK software device with an unauthorized intended use that is different from that cleared under K220989. Namely, the labeling of your device indicates that the NGNK device is now intended to have “device-agnostic compatibility.” During the inspection, your firm’s management explained that “device-agnostic” describes NGNK’s ability to 1) run on any brand of commercial off-the-shelf computer and 2) support input from non-Nihon Kohden devices. However, your device was cleared under K220989 to support inputs from only other Nihon Kohden devices, and not from any device from other manufacturers. Therefore, “device-agnostic compatibility” is beyond the scope of the intended use that was cleared for the Next Generation NetKonnect. This change may introduce patient risks because of the use of additional input devices that have not been validated for compatibility with the NGNK software. Inadequate interoperability can result in incorrect vital sign measurements or loss of expected monitoring, which may result in delay of diagnosis or misdiagnosis. This is a major change or modification in the intended use of the device and requires submission of a 510(k) under 21 CFR 807.81(a)(3)(ii).\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 727803” when replying. If you have any questions about the contents of this letter, please contact: Shaquenta Perkins at shaquenta.perkins@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nCDR Cesar A. Perez, PhD, USPHS\nActing Deputy Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Mr. Arthur E. Webb, Director of Software Quality and Regulatory Affairs, art_webb@nihonkohden.com","Nihon Kohden Digital Health Solutions, LLC","nihon-kohden-digital-health-solutions-llc-727803-06122026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnihon-kohden-digital-health-solutions-llc-727803-06122026","2026-10-26T08:09:33.79279+00:00","2026-07-14","727803","Medical Devices","Harsh Dharwad","2026-08-19T04:30:04.336+00:00","VIA Electronic Mail","2026-06-12",{"id":73,"raw":74,"subject":80,"body_html":81,"body_text":82,"firm_name":83,"letter_id":84,"created_at":85,"fei_number":19,"letter_url":86,"updated_at":87,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":89,"product_type":26,"closeout_date":19,"issuing_office":78,"recipient_name":19,"body_fetched_at":90,"delivery_method":91,"recipient_title":19,"reference_number":19,"action_taken_date":92,"medical_device_id":19,"response_letter_date":19},3698,[75,76,77,78,79,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-08T04:00:00Z\">06\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpublic-health-solution-llc-dba-drmedhealth-728278-06082026\">Public Health Solution LLC dba DrMedHealth\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Public Health Solution LLC dba DrMedHealth\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2003 Plank Road, #1283\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fredericksburg\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>22401\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:support@drmedhealth.com\"> support@drmedhealth.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: MARCS-CMS 728278\u003C\u002Fp>\u003Cp>To DrMedHealth:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of DrMedHealth’s website, https:\u002F\u002Fdrmedhealth.com, FDA Establishment Identifier (FEI) 3044020737, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&amp;C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&amp;C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>More specifically,\u003C\u002Fp>\u003Cp>1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Same active ingredient as Ozempic®”\u003C\u002Fli>\u003Cli>“Same active ingredient as Mounjaro®”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\u003C\u002Fp>\u003Cp>Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&amp;C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&amp;C Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728278 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\u003C\u002Fp>\u003Cp>1. Identifying the entities that produce the compounded drug products offered on your website;\u003C\u002Fp>\u003Cp>2. Providing a representative sample of labeling for such drug products; and\u003C\u002Fp>\u003Cp>3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&amp;C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash, JD\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nPublic Health Solution LLC dba DrMedHealth\n\n2003 Plank Road, #1283\n\nFredericksburg, VA 22401\n\nUnited States\n\nsupport@drmedhealth.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nReference number: MARCS-CMS 728278\nTo DrMedHealth:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of DrMedHealth’s website, https:\u002F\u002Fdrmedhealth.com, FDA Establishment Identifier (FEI) 3044020737, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nYour representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\nMore specifically,\n1. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“Same active ingredient as Ozempic®”\n“Same active ingredient as Mounjaro®”\nCompounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\nAccordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&C Act, including the new drug approval requirements.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728278 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\n1. Identifying the entities that produce the compounded drug products offered on your website;\n2. Providing a representative sample of labeling for such drug products; and\n3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\nPlease note FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash, JD\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n______________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.","Public Health Solution LLC dba DrMedHealth","public-health-solution-llc-dba-drmedhealth-728278-06082026","2026-08-19T04:06:48.349905+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpublic-health-solution-llc-dba-drmedhealth-728278-06082026","2026-10-26T08:09:45.375478+00:00","2026-06-16","728278","2026-08-19T04:36:31.811+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-06-08",{"id":94,"raw":95,"subject":80,"body_html":97,"body_text":98,"firm_name":99,"letter_id":100,"created_at":62,"fei_number":19,"letter_url":101,"updated_at":102,"action_type":22,"case_status":23,"posted_date":88,"marcs_cms_no":103,"product_type":26,"closeout_date":19,"issuing_office":78,"recipient_name":19,"body_fetched_at":104,"delivery_method":91,"recipient_title":19,"reference_number":19,"action_taken_date":92,"medical_device_id":19,"response_letter_date":19},92,[75,76,96,78,79,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnexus-health-solutions-llc-dba-harper-meds-728281-06082026\">Nexus Health Solutions LLC dba Harper Meds\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Nexus Health Solutions LLC dba Harper Meds\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>945 W Side Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jersey City\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07306\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:care@harpermeds.com\"> care@harpermeds.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: MARCS-CMS 728281\u003C\u002Fp>\u003Cp>To Harper Meds:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of Harper Meds’ website, https:\u002F\u002Fwww.harpermeds.com, FDA Establishment Identifier (FEI) 3044020867, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&amp;C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&amp;C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>More specifically,\u003C\u002Fp>\u003Cp>1. The compounded semaglutide and tirzepatide products displayed on your website identify “Harper Meds” on the pictured label, suggesting Harper Meds is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>2. The following claims concerning compounded semaglutide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Same active ingredient as Ozempic™ &amp; Wegovy™”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\u003C\u002Fp>\u003Cp>3. Your website claims that the compounded drug products it offers are sourced from “FDA-licensed 503A Outsourcing Facilities.” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities. The FD&amp;C Act does not establish an “FDA-approved” or “FDA-licensed” designation for pharmacies or outsourcing facilities.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Therefore, representing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed” is false and misleading, as these terms imply a formal authorization that FDA does not grant to such entities or their compounded products.\u003C\u002Fp>\u003Cp>Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&amp;C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&amp;C Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728281 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\u003C\u002Fp>\u003Cp>1. Identifying the entities that produce the compounded drug products offered on your website;\u003C\u002Fp>\u003Cp>2. Providing a representative sample of labeling for such drug products; and\u003C\u002Fp>\u003Cp>3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&amp;C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash, JD\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); see also FD&amp;C Act § 503(b) [21 U.S.C. § 353(b)], FD&amp;C Act § 503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 C.F.R. § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1….”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 U.S.C. § 353(b)(2)].\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> While an entity may elect to register with FDA as an outsourcing facility under section 503B of the FD&amp;C Act [21 U.S.C. § 353b], this registration does not constitute FDA approval or licensure of the facility or its compounded drug products. Neither compounders operating under section 503A nor outsourcing facilities operating under section 503B undergo FDA premarket review or approval of their compounded drug products. Compounded drug products are not FDA-approved drugs; they have not been evaluated by FDA for safety, effectiveness, or quality before marketing as is required for new drug applications (NDAs) or abbreviated new drug applications (ANDAs).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nNexus Health Solutions LLC dba Harper Meds\n\n945 W Side Ave\n\nJersey City, NJ 07306\n\nUnited States\n\ncare@harpermeds.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nReference number: MARCS-CMS 728281\nTo Harper Meds:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of Harper Meds’ website, https:\u002F\u002Fwww.harpermeds.com, FDA Establishment Identifier (FEI) 3044020867, in March 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nYour representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\nMore specifically,\n1. The compounded semaglutide and tirzepatide products displayed on your website identify “Harper Meds” on the pictured label, suggesting Harper Meds is the compounder of those drugs when in fact it is not.2\n2. The following claims concerning compounded semaglutide products appear on your website:\n“Same active ingredient as Ozempic™ & Wegovy™”\nCompounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\n3. Your website claims that the compounded drug products it offers are sourced from “FDA-licensed 503A Outsourcing Facilities.” Compounding facilities, including pharmacies and outsourcing facilities, are not “FDA-approved” or “FDA-licensed” entities. The FD&C Act does not establish an “FDA-approved” or “FDA-licensed” designation for pharmacies or outsourcing facilities.3 Therefore, representing a compounding pharmacy or outsourcing facility as “FDA-approved” or “FDA-licensed” is false and misleading, as these terms imply a formal authorization that FDA does not grant to such entities or their compounded products.\nAccordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&C Act, including the new drug approval requirements.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728281 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\n1. Identifying the entities that produce the compounded drug products offered on your website;\n2. Providing a representative sample of labeling for such drug products; and\n3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\nPlease note FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash, JD\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n________________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); see also FD&C Act § 503(b) [21 U.S.C. § 353(b)], FD&C Act § 503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 C.F.R. § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1….”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 U.S.C. § 353(b)(2)].\n3 While an entity may elect to register with FDA as an outsourcing facility under section 503B of the FD&C Act [21 U.S.C. § 353b], this registration does not constitute FDA approval or licensure of the facility or its compounded drug products. Neither compounders operating under section 503A nor outsourcing facilities operating under section 503B undergo FDA premarket review or approval of their compounded drug products. Compounded drug products are not FDA-approved drugs; they have not been evaluated by FDA for safety, effectiveness, or quality before marketing as is required for new drug applications (NDAs) or abbreviated new drug applications (ANDAs).","Nexus Health Solutions LLC dba Harper Meds","nexus-health-solutions-llc-dba-harper-meds-728281-06082026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnexus-health-solutions-llc-dba-harper-meds-728281-06082026","2026-10-26T08:09:33.153446+00:00","728281","2026-08-19T04:36:09.166+00:00",{"id":106,"raw":107,"subject":111,"body_html":112,"body_text":113,"firm_name":114,"letter_id":115,"created_at":116,"fei_number":19,"letter_url":117,"updated_at":118,"action_type":22,"case_status":23,"posted_date":119,"marcs_cms_no":120,"product_type":67,"closeout_date":19,"issuing_office":56,"recipient_name":19,"body_fetched_at":121,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":122,"medical_device_id":19,"response_letter_date":19},3127,[108,109,110,56,111,13,13,13],"\u003Ctime datetime=\"2021-10-05T13:20:00Z\">10\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-09T04:00:00Z\">08\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpairon-solutions-llc-616392-08092021\">Pairon Solutions LLC\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Pairon Solutions LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13970 SW 72nd Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Portland\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97223\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:melissa@paironsolutions.com\"> melissa@paironsolutions.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>DATE: August 9, 2021\u003Cbr>\n\u003Cbr>\nRe: “Arun KN95 Folding Face Mask,” “Deming Surgical Mask,” and “Pairon 3Ply Face Mask” (Blue, White &amp; Black)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.paironsolutionsppe.com\u002F on July 14, 2021. The FDA has observed that your website offers the “Arun KN95 Folding Face Mask,” the “Deming Surgical Mask”, and the “Pairon 3Ply Face Mask” (Blue, White &amp; Black) for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your website revealed the following statements that establish that the Arun KN95 Folding Face Mask, Deming Surgical Mask, and Pairon 3Ply Face Mask (Blue, White &amp; Black) are intended for the mitigation, prevention, treatment, diagnosis, or cure of disease, including but not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Statements made alongside an image of the Arun KN95 Folding Face Mask that it is “listed on FDA EUA for Non-NIOSH Devices” and representing compliance with “GB2626-2006” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Statements alongside an image of the Deming Surgical Mask that it provides “99% bacterial efficiency” and “complies ASTM F2100”. The name also incorporates the word “surgical” as well as “medical” written on the box packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Statements made on the packaging and alongside the images of the Pairon 3Ply Face Mask (Blue, White &amp; Black) that they provide “&gt;95% bacterial efficiency” and “helps filter out … bacteria” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-facemask], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\u003C\u002Fli>\n\t\u003Cli>Statements on your firm’s customer blog page representing that the BLUE – Pairon 3Ply Face Mask has been supplied to nursing home facilities [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fblogs\u002Fnews]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Based on our review, your website is offering for sale in the United States, the Arun KN95 Folding Face Mask (which your website represents is manufactured by Dongguan Arun Industrial Co. Ltd.), the Deming Surgical Mask (which your website represents is manufactured by Xiantao Deming Healthcare Products Co., Ltd.), and the Pairon 3Ply Face Mask - Blue, White &amp; Black (which your website represents is manufactured by Wuxi Hingdou Sports Co., Ltd) without marketing approval or clearance from the FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>In addition, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. See 21 CFR 807.39.\u003C\u002Fp>\n\n\u003Cp>Your website contains a number of false or misleading representations, including but not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Representations that the Arun KN95 Folding Face Masks are “Certified: … FDA” and unauthorized display of what appears to be FDA’s logo\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on inner packaging of the product [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Representations that the Deming Surgical Masks are “Certified: FDA” and unauthorized display of what appears to be FDA’s logo on packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Representations that Pairon 3Ply Face Masks (Blue, White &amp; Black) are “FDA Registered” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask] [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black][https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\u003C\u002Fli>\n\t\u003Cli>Unauthorized display of what appears to be FDA’s logo alongside the BLACK – Pairon&nbsp;3Ply Face Mask [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3plyface-mask-black]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certificate of FDA Registration” issued by “UCL-REGSERVICE INC” (UCL-REGSERVICE Certificate) alongside Arun KN95 Folding Face Mask product information. The UCL-REGSERVICE Certificate “certifies that Dongguan Arun Industrial Co. Ltd., …has completed the FDA Establishment Registration and Device Listing with the US Food &amp; Drug Administration…” The UCL-REGSERVICE Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certification of Registration” issued by “Sungo Technical Services Inc.” (Sungo Technical Certificate) alongside Deming Surgical Mask product information. The Sungo Technical Certificate “certifies that Xiantao Deming Healthcare Products Co., Ltd., … has completed the FDA Establishment Registration and Device Listing with the US Food &amp; Drug Administration…” The Sungo Technical Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certification of Registration” issued by “Wayborn Quality &amp; Technology Services” (Wayborn Certificate) alongside the BLUE – Pairon 3Ply Face Mask product information. The Wayborn Certificate “certifies that … Wuxi Hingdou Sports Co., Ltd., …has completed U.S. FOOD And DRUG Administration Medical Device Registration…” The Wayborn Certificate has the look of an official government document and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>To date, FDA has not cleared, approved, authorized or “Certified” the Arun KN95 Folding Face Mask or the Deming Surgical Mask offered for sale by your firm, and so statements to the contrary are false. In addition, display of the FDA logo on packaging and near images of and information about the Arun KN95 Folding Face Mask, the Deming Surgical Mask, and the Pairon 3Ply Face Mask (Blue, White &amp; Black), combined with statements such as, “Certified: FDA” and “FDA Registered”, are misleading because it creates the impression of official FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the devices and\u002For your establishment.. The UCL-REGSERVICE Certificate bearing the FDA logo, positioned near images of and information about the Arun KN95 Folding Face Mask is misleading because it implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Dongguan Arun Industrial, Co., Ltd. is or was registered with FDA and that the firm is or was in possession of a registration number. In addition, the display of Sungo Technical Certificate bearing the FDA logo positioned near images of and information about the Deming Surgical Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Xiantao Deming Healthcare Products Co., Ltd. registration and possession of a registration number. Furthermore, display of the Wayborn Certificate bearing the FDA logo, near information about the BLUE – Pairon 3Ply Face Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Wuxi Hingdou Sports Co., Ltd registration and possession of a registration number. Although the Arun KN95 Folding Face Mask, Deming Surgical Mask, and BLUE – Pairon 3Ply Face Mask Certificates contain legible language that appears to be intended to function as a disclaimer, including a statement that the Certificates do not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificates. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>We remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration &amp; Device Listing Database merely denotes that the establishment has provided certain information to FDA.\u003C\u002Fp>\n\n\u003Cp>This letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the Document number CMS Case# 616392 or CTS Number CPT2001233 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donna Engleman, MS, BSN\u003Cbr>\nDirector\u003Cbr>\nDivision of Market Intelligence\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>Yabo Zhang\u003Cbr>\nDongguan Arun Industrial, Co., Ltd.\u003Cbr>\nNO.18Xingfeng St, Changlong, Huangjiang\u003Cbr>\nDongguan, CN 523766\u003C\u002Fp>\n\n\u003Cp>US Agent:\u003Cbr>\nSimcal\u003Cbr>\nUCL-REG SERVICE INC.\u003Cbr>\n3907 Prince Street Suite 6F\u003Cbr>\nFlushing, NY 11354\u003Cbr>\nEmail: gbstandard@163.com\u003C\u002Fp>\n\n\u003Cp>UCL-Reg Service\u003Cbr>\n602 ROCKWOOD ROAD, WILMINGTON\u003Cbr>\nNew Castle, DE, 19802\u003C\u002Fp>\n\n\u003Cp>XIANTAO DEMING HEALTHCARE PRODUCTS CO., LTD.\u003Cbr>\nNo.198, Pengchang Ave. Pengchang Town, Xiantao City\u003Cbr>\nHubei Province, P.R. China\u003Cbr>\nXiantao, CN 433018\u003C\u002Fp>\n\n\u003Cp>Leeyeo Kee\u003Cbr>\nRegrek LLC\u003Cbr>\n19 Holly Cove Ln.\u003Cbr>\nDover, DE 19901\u003Cbr>\nEmail: regrek.cs@hotmail.com\u003C\u002Fp>\n\n\u003Cp>Sungo Technical Services Inc.\u003Cbr>\n6050 W Eastwood Ave Apt. 201 Chicago Illinois 60630\u003Cbr>\nE-mail：sungo.group@yahoo.com\u003Cbr>\nEmail: Shage2008@126.com\u003C\u002Fp>\n\n\u003Cp>WUXI HINGDOU SPORTS CO., LTD\u003Cbr>\nHongdou Industrial Park, Donggang Town\u003Cbr>\nWuxi, Jiangsu, 214000, China\u003C\u002Fp>\n\n\u003Cp>Director: Crane Yu\u003Cbr>\nWayborn Quality &amp; Technology Services\u003Cbr>\n306, Xincheng International Main Building,\u003Cbr>\nNo.535 Qingshuiqiao Road, Ningbo High-tech Zone\u003Cbr>\nEmail: wayborn@wayb.org\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\">https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\u003C\u002Fa>)\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nPairon Solutions LLC\n\n13970 SW 72nd Ave\n\nPortland, OR 97223\n\nUnited States\n\nmelissa@paironsolutions.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDATE: August 9, 2021\n\nRe: “Arun KN95 Folding Face Mask,” “Deming Surgical Mask,” and “Pairon 3Ply Face Mask” (Blue, White & Black)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.paironsolutionsppe.com\u002F on July 14, 2021. The FDA has observed that your website offers the “Arun KN95 Folding Face Mask,” the “Deming Surgical Mask”, and the “Pairon 3Ply Face Mask” (Blue, White & Black) for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your website revealed the following statements that establish that the Arun KN95 Folding Face Mask, Deming Surgical Mask, and Pairon 3Ply Face Mask (Blue, White & Black) are intended for the mitigation, prevention, treatment, diagnosis, or cure of disease, including but not limited to:\n\nStatements made alongside an image of the Arun KN95 Folding Face Mask that it is “listed on FDA EUA for Non-NIOSH Devices” and representing compliance with “GB2626-2006” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nStatements alongside an image of the Deming Surgical Mask that it provides “99% bacterial efficiency” and “complies ASTM F2100”. The name also incorporates the word “surgical” as well as “medical” written on the box packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nStatements made on the packaging and alongside the images of the Pairon 3Ply Face Mask (Blue, White & Black) that they provide “>95% bacterial efficiency” and “helps filter out … bacteria” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-facemask], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\n\nStatements on your firm’s customer blog page representing that the BLUE – Pairon 3Ply Face Mask has been supplied to nursing home facilities [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fblogs\u002Fnews]\n\nBased on our review, your website is offering for sale in the United States, the Arun KN95 Folding Face Mask (which your website represents is manufactured by Dongguan Arun Industrial Co. Ltd.), the Deming Surgical Mask (which your website represents is manufactured by Xiantao Deming Healthcare Products Co., Ltd.), and the Pairon 3Ply Face Mask - Blue, White & Black (which your website represents is manufactured by Wuxi Hingdou Sports Co., Ltd) without marketing approval or clearance from the FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nIn addition, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. See 21 CFR 807.39.\n\nYour website contains a number of false or misleading representations, including but not limited to:\n\nRepresentations that the Arun KN95 Folding Face Masks are “Certified: … FDA” and unauthorized display of what appears to be FDA’s logo1 on inner packaging of the product [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nRepresentations that the Deming Surgical Masks are “Certified: FDA” and unauthorized display of what appears to be FDA’s logo on packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nRepresentations that Pairon 3Ply Face Masks (Blue, White & Black) are “FDA Registered” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask] [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black][https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\n\nUnauthorized display of what appears to be FDA’s logo alongside the BLACK – Pairon 3Ply Face Mask [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3plyface-mask-black]\n\nDisplaying a “Certificate of FDA Registration” issued by “UCL-REGSERVICE INC” (UCL-REGSERVICE Certificate) alongside Arun KN95 Folding Face Mask product information. The UCL-REGSERVICE Certificate “certifies that Dongguan Arun Industrial Co. Ltd., …has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” The UCL-REGSERVICE Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo1 and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nDisplaying a “Certification of Registration” issued by “Sungo Technical Services Inc.” (Sungo Technical Certificate) alongside Deming Surgical Mask product information. The Sungo Technical Certificate “certifies that Xiantao Deming Healthcare Products Co., Ltd., … has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” The Sungo Technical Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nDisplaying a “Certification of Registration” issued by “Wayborn Quality & Technology Services” (Wayborn Certificate) alongside the BLUE – Pairon 3Ply Face Mask product information. The Wayborn Certificate “certifies that … Wuxi Hingdou Sports Co., Ltd., …has completed U.S. FOOD And DRUG Administration Medical Device Registration…” The Wayborn Certificate has the look of an official government document and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask]\n\nTo date, FDA has not cleared, approved, authorized or “Certified” the Arun KN95 Folding Face Mask or the Deming Surgical Mask offered for sale by your firm, and so statements to the contrary are false. In addition, display of the FDA logo on packaging and near images of and information about the Arun KN95 Folding Face Mask, the Deming Surgical Mask, and the Pairon 3Ply Face Mask (Blue, White & Black), combined with statements such as, “Certified: FDA” and “FDA Registered”, are misleading because it creates the impression of official FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the devices and\u002For your establishment.. The UCL-REGSERVICE Certificate bearing the FDA logo, positioned near images of and information about the Arun KN95 Folding Face Mask is misleading because it implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Dongguan Arun Industrial, Co., Ltd. is or was registered with FDA and that the firm is or was in possession of a registration number. In addition, the display of Sungo Technical Certificate bearing the FDA logo positioned near images of and information about the Deming Surgical Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Xiantao Deming Healthcare Products Co., Ltd. registration and possession of a registration number. Furthermore, display of the Wayborn Certificate bearing the FDA logo, near information about the BLUE – Pairon 3Ply Face Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Wuxi Hingdou Sports Co., Ltd registration and possession of a registration number. Although the Arun KN95 Folding Face Mask, Deming Surgical Mask, and BLUE – Pairon 3Ply Face Mask Certificates contain legible language that appears to be intended to function as a disclaimer, including a statement that the Certificates do not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificates. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\n\nWe remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration & Device Listing Database merely denotes that the establishment has provided certain information to FDA.\n\nThis letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the Document number CMS Case# 616392 or CTS Number CPT2001233 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonna Engleman, MS, BSN\n\nDirector\n\nDivision of Market Intelligence\n\nOffice of Regulatory Programs\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nYabo Zhang\n\nDongguan Arun Industrial, Co., Ltd.\n\nNO.18Xingfeng St, Changlong, Huangjiang\n\nDongguan, CN 523766\n\nUS Agent:\n\nSimcal\n\nUCL-REG SERVICE INC.\n\n3907 Prince Street Suite 6F\n\nFlushing, NY 11354\n\nEmail: gbstandard@163.com\n\nUCL-Reg Service\n\n602 ROCKWOOD ROAD, WILMINGTON\n\nNew Castle, DE, 19802\n\nXIANTAO DEMING HEALTHCARE PRODUCTS CO., LTD.\n\nNo.198, Pengchang Ave. Pengchang Town, Xiantao City\n\nHubei Province, P.R. China\n\nXiantao, CN 433018\n\nLeeyeo Kee\n\nRegrek LLC\n\n19 Holly Cove Ln.\n\nDover, DE 19901\n\nEmail: regrek.cs@hotmail.com\n\nSungo Technical Services Inc.\n\n6050 W Eastwood Ave Apt. 201 Chicago Illinois 60630\n\nE-mail：sungo.group@yahoo.com\n\nEmail: Shage2008@126.com\n\nWUXI HINGDOU SPORTS CO., LTD\n\nHongdou Industrial Park, Donggang Town\n\nWuxi, Jiangsu, 214000, China\n\nDirector: Crane Yu\n\nWayborn Quality & Technology Services\n\n306, Xincheng International Main Building,\n\nNo.535 Qingshuiqiao Road, Ningbo High-tech Zone\n\nEmail: wayborn@wayb.org\n\n___________________________\n\n1 The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy)","Pairon Solutions LLC","pairon-solutions-llc-616392-08092021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpairon-solutions-llc-616392-08092021","2026-10-26T08:09:39.952179+00:00","2021-10-05","616392","2026-08-20T02:35:05.169+00:00","2021-08-09",{"id":124,"raw":125,"subject":131,"body_html":132,"body_text":133,"firm_name":134,"letter_id":135,"created_at":62,"fei_number":19,"letter_url":136,"updated_at":137,"action_type":22,"case_status":138,"posted_date":139,"marcs_cms_no":140,"product_type":26,"closeout_date":141,"issuing_office":78,"recipient_name":142,"body_fetched_at":143,"delivery_method":91,"recipient_title":19,"reference_number":19,"action_taken_date":144,"medical_device_id":19,"response_letter_date":19},222,[126,127,128,78,129,13,130,13],"\u003Ctime datetime=\"2026-04-21T04:00:00Z\">04\u002F21\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-09T05:00:00Z\">02\u002F09\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthrive-health-and-wellness-llc-dba-thrive-health-solutions-714891-02092026\">Thrive Health and Wellness, LLC dba Thrive Health Solutions \u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products ","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthrive-health-and-wellness-llc-dba-thrive-health-solutions-714891-07272026\">\u003Ctime datetime=\"2026-08-06T04:00:00Z\">08\u002F06\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Doug Hatch\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Thrive Health and Wellness, LLC dba Thrive Health Solutions \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>88 Inverness Circle East, Ste A-204\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Englewood\u003C\u002Fspan>, \u003Cspan>CO\u003C\u002Fspan> \u003Cspan>80112-5521\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>WL # 714891\u003C\u002Fp>\u003Cp>February 9, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Hatch:\u003C\u002Fp>\u003Cp>From March 25, 2025, to April 3, 2025, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, Thrive Health and Wellness, LLC dba Thrive Health Solutions, located at 88 Inverness Circle E Ste A-204, Englewood, CO 80112. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 to your firm on April 3, 2025. FDA acknowledges receipt of your facility’s response, dated April 22, 2025. FDA further acknowledges that as of April 21, 2025, your firm ceased repackaging of sterile drug products not intended for immediate use. FDA also acknowledges that on May 21, 2025, your firm initiated a voluntary recall of all repackaged sterile drug products dispensed between January 2, 2025, to April 18, 2025, due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products Under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Section 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\u003C\u002Fp>\u003Cp>1. Your personnel were observed conducting aseptic operations outside of a certified ISO 5 area. More specifically, your personnel filled sterile drug products into syringes on a benchtop table located in an unclassified room that shared the workspace with a blood sample centrifuge. These drug products were not intended for immediate administration to patients but were distributed for future administration outside your facility.\u003C\u002Fp>\u003Cp>2. Your personnel performing sterile operations have never performed media fills. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\u003Cp>3. Your aseptic processing and surrounding areas had difficult to clean equipment and surfaces. For example, your entire facility flooring was covered with carpet.\u003C\u002Fp>\u003Cp>4. Your personnel engaged in aseptic processing while wearing non-sterile gloves and with exposed hair and skin.\u003C\u002Fp>\u003Cp>5. Your firm failed to use a sporicidal agent as part of your disinfection program for the aseptic processing area and used non-sterile wipes to clean within the area where drug products were filled into syringes.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not have any FDA-approved applications on file for the drug products that you repackage, such as NAD+ 50 mg\u002FmL and MEGALean (Tirzepatide\u002FCyanocobalamin) Injections 10mg\u002F20mg\u002FmL.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> These products are unapproved new drugs under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)]. A new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505\u003Cbr>of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application is prohibited under section 301(d) of the FDCA [21 U.S.C. § 331(d)].\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The drug products you repackage, such as NAD+ 50 mg\u002FmL and MEGALean (Tirzepatide\u002FCyanocobalamin) Injections 10mg\u002F20mg\u002FmL, are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction of misbranded drugs into interstate commerce is prohibited under section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your facility’s response to the Form FDA 483. We acknowledge that as of April 21, 2025, your firm ceased repackaging of sterile drug products not intended for immediate use. We also acknowledge that on May 21, 2025, your firm initiated a voluntary recall of all repackaged sterile drug products dispensed between January 2, 2025, to April 18, 2025, due to a lack of sterility assurance.\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>If you decide to resume operations to produce sterile drug products not intended for immediate use, you should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address any violations, or you may inform us that you do not intend to resume production of sterile drug products not intended for immediate use. If you intend to resume production of sterile drug products not intended for immediate use in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any drugs intended or expected to be sterile in the future.\u003C\u002Fp>\u003Cp>Your response and any questions regarding the contents of this letter should be sent to compoundinginspections@fda.hhs.gov. In your response, refer to the Warning Letter Number above (# 714891) and include a subject line that clearly identifies the submission as a Response to Warning Letter.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The specific products repackaged by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3 \u003C\u002Fstrong>\u003C\u002Fem>Drugs that are repackaged are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. For additional information, you may wish to review FDA’s 2017 guidance document, “Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities.” More specifically, the guidance sets forth conditions under which FDA does not intend to take action against drug products repackaged by pharmacies and outsourcing facilities for certain violations of the FDCA. Such conditions include, but are not limited to, the drug product that is being repackaged is a prescription drug product that (1) is approved under section 505 of the FDCA; or (2) is an unapproved drug product that appears on the drug shortage list in effect under section 506E of the FDCA, and the repackaged drug product is distributed during any period in which it is listed on that drug shortage list or during the 30 days following such period.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> The drug products you repackage, such as NAD+ 50 mg\u002FmL and MEGALean (Tirzepatide\u002FCyanocobalamin) Injections 10mg\u002F20mg\u002FmL, are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nDoug Hatch\n\nRecipient Title\n\nOwner\n\nThrive Health and Wellness, LLC dba Thrive Health Solutions\n\n88 Inverness Circle East, Ste A-204\n\nEnglewood, CO 80112-5521\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nWL # 714891\nFebruary 9, 2026\nDear Mr. Hatch:\nFrom March 25, 2025, to April 3, 2025, a U.S. Food and Drug Administration (FDA) investigator inspected your facility, Thrive Health and Wellness, LLC dba Thrive Health Solutions, located at 88 Inverness Circle E Ste A-204, Englewood, CO 80112. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\nFDA issued a Form FDA 483 to your firm on April 3, 2025. FDA acknowledges receipt of your facility’s response, dated April 22, 2025. FDA further acknowledges that as of April 21, 2025, your firm ceased repackaging of sterile drug products not intended for immediate use. FDA also acknowledges that on May 21, 2025, your firm initiated a voluntary recall of all repackaged sterile drug products dispensed between January 2, 2025, to April 18, 2025, due to a lack of sterility assurance. Based on this inspection, it appears that you produced drug products that violate the Federal Food, Drug, and Cosmetic Act (FDCA).\nA. Compounded Drug Products Under the FDCA\nSection 503A of the FDCA describes the conditions under which human drug products compounded by a licensed pharmacist in a State licensed pharmacy or a Federal facility, or a licensed physician, qualify for exemptions from three sections of the FDCA: compliance with current good manufacturing practice (CGMP) (section 501(a)(2)(B)); labeling with adequate directions for use (section 502(f)(1)); and FDA approval prior to marketing (section 505) [21 U.S.C. §§ 351(a)(2)(B), 352(f)(1) and 355(a)].1\nB. Violations of the FDCA\nAdulterated Drug Products\nThe FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator observed that:\n1. Your personnel were observed conducting aseptic operations outside of a certified ISO 5 area. More specifically, your personnel filled sterile drug products into syringes on a benchtop table located in an unclassified room that shared the workspace with a blood sample centrifuge. These drug products were not intended for immediate administration to patients but were distributed for future administration outside your facility.\n2. Your personnel performing sterile operations have never performed media fills. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n3. Your aseptic processing and surrounding areas had difficult to clean equipment and surfaces. For example, your entire facility flooring was covered with carpet.\n4. Your personnel engaged in aseptic processing while wearing non-sterile gloves and with exposed hair and skin.\n5. Your firm failed to use a sporicidal agent as part of your disinfection program for the aseptic processing area and used non-sterile wipes to clean within the area where drug products were filled into syringes.\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\nUnapproved New Drug Products\nYou do not have any FDA-approved applications on file for the drug products that you repackage, such as NAD+ 50 mg\u002FmL and MEGALean (Tirzepatide\u002FCyanocobalamin) Injections 10mg\u002F20mg\u002FmL.2 These products are unapproved new drugs under sections 505(a) and 301(d) of the FDCA [21 U.S.C. § 331(d)]. A new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505\nof the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application is prohibited under section 301(d) of the FDCA [21 U.S.C. § 331(d)].3\nMisbranded Drug Products\nThe drug products you repackage, such as NAD+ 50 mg\u002FmL and MEGALean (Tirzepatide\u002FCyanocobalamin) Injections 10mg\u002F20mg\u002FmL, are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses.4 Accordingly, these drug products are misbranded under section 502(f)(1) of the FDCA. The introduction or delivery for introduction of misbranded drugs into interstate commerce is prohibited under section 301(a) of the FDCA. It is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\nC. Corrective Actions\nWe have reviewed your facility’s response to the Form FDA 483. We acknowledge that as of April 21, 2025, your firm ceased repackaging of sterile drug products not intended for immediate use. We also acknowledge that on May 21, 2025, your firm initiated a voluntary recall of all repackaged sterile drug products dispensed between January 2, 2025, to April 18, 2025, due to a lack of sterility assurance.\nD. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nIf you decide to resume operations to produce sterile drug products not intended for immediate use, you should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to address any violations, or you may inform us that you do not intend to resume production of sterile drug products not intended for immediate use. If you intend to resume production of sterile drug products not intended for immediate use in the future, please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. In addition to taking appropriate corrective actions, you should notify this office fifteen (15) working days prior to resuming production of any drugs intended or expected to be sterile in the future.\nYour response and any questions regarding the contents of this letter should be sent to compoundinginspections@fda.hhs.gov. In your response, refer to the Warning Letter Number above (# 714891) and include a subject line that clearly identifies the submission as a Response to Warning Letter.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n______________________\n1 We remind you that there are conditions other than those discussed in this letter that must be satisfied to qualify for the exemptions in section 503A of the FDCA.\n2 The specific products repackaged by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n3 Drugs that are repackaged are not eligible for the exemptions for compounded drugs under sections 503A and 503B of the FDCA. For additional information, you may wish to review FDA’s 2017 guidance document, “Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities.” More specifically, the guidance sets forth conditions under which FDA does not intend to take action against drug products repackaged by pharmacies and outsourcing facilities for certain violations of the FDCA. Such conditions include, but are not limited to, the drug product that is being repackaged is a prescription drug product that (1) is approved under section 505 of the FDCA; or (2) is an unapproved drug product that appears on the drug shortage list in effect under section 506E of the FDCA, and the repackaged drug product is distributed during any period in which it is listed on that drug shortage list or during the 30 days following such period.\n4 The drug products you repackage, such as NAD+ 50 mg\u002FmL and MEGALean (Tirzepatide\u002FCyanocobalamin) Injections 10mg\u002F20mg\u002FmL, are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).","Thrive Health and Wellness, LLC dba Thrive Health Solutions","thrive-health-and-wellness-llc-dba-thrive-health-solutions-714891-02092026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fthrive-health-and-wellness-llc-dba-thrive-health-solutions-714891-02092026","2026-10-26T08:10:11.920103+00:00","Closed Out","2026-04-21","714891","2026-08-06","Doug Hatch","2026-08-19T04:47:00.798+00:00","2026-02-09",{"id":146,"raw":147,"subject":151,"body_html":152,"body_text":153,"firm_name":154,"letter_id":155,"created_at":156,"fei_number":19,"letter_url":157,"updated_at":158,"action_type":22,"case_status":23,"posted_date":159,"marcs_cms_no":160,"product_type":161,"closeout_date":19,"issuing_office":78,"recipient_name":162,"body_fetched_at":163,"delivery_method":91,"recipient_title":19,"reference_number":164,"action_taken_date":165,"medical_device_id":19,"response_letter_date":19},22012,[148,149,150,78,151,13,13,13],"\u003Ctime datetime=\"2026-10-27T04:00:00Z\">10\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-22T04:00:00Z\">10\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftsp-solutions-pte-ltd-735071-10222026\">TSP Solutions Pte. Ltd.\u003C\u002Fa>","Request for Records\u002FCGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-07\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Min-tsek Lau\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>TSP Solutions Pte. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Block 998 Toa Payoh North\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>#05-05\u002F06 Mapletree Industrial\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>318993\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Singapore\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mintsek@tspsolutions.co\"> mintsek@tspsolutions.co\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 22, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-27-07\u003C\u002Fp>\u003Cp>To Mr. Min-tsek Lau:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during review of your drug manufacturing facility, TSP Solutions Pte. Ltd., FDA Establishment Identifier (FEI) 3023093622. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 9, 2025, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release; and, your firm failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures sunscreen drug products.\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that you conduct adequate finished drug product testing on your drug products. Specifically, neither the certificate of analysis (COA) reports nor the batch records that you provided include an appropriate assay test for active ingredient content or impurity testing. In addition, your records do not include appropriate microbiological testing.\u003C\u002Fp>\u003Cp>Full release testing, including strength and identity testing of the active ingredient, as well as appropriate microbiological testing, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to ensure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a lot disposition decision.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that you are adequately testing the identity of incoming components used in the manufacture of your drug products. Your response also indicated that you accept your supplier’s COA without verifying the test results at appropriate intervals. Verification of component quality is performed only by reviewing the COAs and material safety data sheets provided by the suppliers.\u003C\u002Fp>\u003Cp>Without adequate testing and without establishing the reliability of your component suppliers’ test analyses at appropriate intervals, you do not have scientific evidence that your raw materials conform to appropriate specifications before you use them in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before you use them in production to ensure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality based on thorough historical review\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data)\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\u003Cbr>o vigilant lifecycle monitoring of all suppliers using sound quality risk management practices\u003Cbr>o based on this thorough review, summarize a systemic CAPA that remediates the materials system to ensure ongoing lifecycle oversight of vendor performance and prevents use of unsuitable components (ingredients), containers and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Adequate procedures ensuring appropriate production and process controls for drug product manufacturing and qualification of equipment used to manufacture drug products (21 CFR 211.100(a)).\u003C\u002Fli>\u003Cli>Adequate laboratory control procedures to ensure drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fli>\u003Cli>The establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 14, 2026.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at TSP Solutions Pte. Ltd., at Block 998 Toa Payoh North, #05-05\u002F06 Mapletree Industrial, Singapore 318993, Singapore, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within 15 business days of receipt of this letter. Identify your written response with FEI 3023093622 and ATTN: Bryce Hammer in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>Cc: Registered U.S. Agent\u003Cbr>Mr. David Lennarz\u003Cbr>Registrar Corp\u003Cbr>drugs@registrarcorp.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-07\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Min-tsek Lau\n\nRecipient Title\n\nManaging Director\n\nTSP Solutions Pte. Ltd.\n\nBlock 998 Toa Payoh North\n\n#05-05\u002F06 Mapletree Industrial\n\n318993\n\nSingapore\n\nmintsek@tspsolutions.co\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 22, 2026\nWARNING LETTER\nReference number: 320-27-07\nTo Mr. Min-tsek Lau:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\nFDA Review\nViolations were identified and documented during review of your drug manufacturing facility, TSP Solutions Pte. Ltd., FDA Establishment Identifier (FEI) 3023093622. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 9, 2025, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release; and, your firm failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\nYour firm manufactures sunscreen drug products.\nBased on the records and information you provided, you did not demonstrate that you conduct adequate finished drug product testing on your drug products. Specifically, neither the certificate of analysis (COA) reports nor the batch records that you provided include an appropriate assay test for active ingredient content or impurity testing. In addition, your records do not include appropriate microbiological testing.\nFull release testing, including strength and identity testing of the active ingredient, as well as appropriate microbiological testing, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to ensure that your drug products conform to appropriate specifications before release.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a lot disposition decision.\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nBased on the records and information you provided, you did not demonstrate that you are adequately testing the identity of incoming components used in the manufacture of your drug products. Your response also indicated that you accept your supplier’s COA without verifying the test results at appropriate intervals. Verification of component quality is performed only by reviewing the COAs and material safety data sheets provided by the suppliers.\nWithout adequate testing and without establishing the reliability of your component suppliers’ test analyses at appropriate intervals, you do not have scientific evidence that your raw materials conform to appropriate specifications before you use them in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before you use them in production to ensure adequate quality.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\no an assessment of all materials to determine whether they are consistently of acceptable quality based on thorough historical review\no a review to ensure assigned expiration or retest dates are appropriate (supported by data)\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\no vigilant lifecycle monitoring of all suppliers using sound quality risk management practices\no based on this thorough review, summarize a systemic CAPA that remediates the materials system to ensure ongoing lifecycle oversight of vendor performance and prevents use of unsuitable components (ingredients), containers and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\n3. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nBased on the records and information you provided, your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure:\nAdequate procedures ensuring appropriate production and process controls for drug product manufacturing and qualification of equipment used to manufacture drug products (21 CFR 211.100(a)).\nAdequate laboratory control procedures to ensure drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nThe establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\nYour firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 14, 2026.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at TSP Solutions Pte. Ltd., at Block 998 Toa Payoh North, #05-05\u002F06 Mapletree Industrial, Singapore 318993, Singapore, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within 15 business days of receipt of this letter. Identify your written response with FEI 3023093622 and ATTN: Bryce Hammer in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nCc: Registered U.S. Agent\nMr. David Lennarz\nRegistrar Corp\ndrugs@registrarcorp.com","TSP Solutions Pte. Ltd.","tsp-solutions-pte-ltd-735071-10222026","2026-11-03T01:02:17.615107+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftsp-solutions-pte-ltd-735071-10222026","2026-11-17T01:02:03.701861+00:00","2026-10-27","735071","Drugs Over-the-Counter Drugs","Mr. Min-tsek Lau","2026-11-03T01:03:12.526+00:00","320-27-07","2026-10-22",{"id":167,"raw":168,"subject":173,"body_html":174,"body_text":175,"firm_name":176,"letter_id":177,"created_at":178,"fei_number":19,"letter_url":179,"updated_at":180,"action_type":22,"case_status":23,"posted_date":181,"marcs_cms_no":182,"product_type":26,"closeout_date":19,"issuing_office":172,"recipient_name":183,"body_fetched_at":184,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":185,"medical_device_id":19,"response_letter_date":19},1227,[169,170,171,172,173,13,13,13],"\u003Ctime datetime=\"2024-10-01T13:20:00Z\">10\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-06T04:00:00Z\">09\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fclean-solutions-llc-686995-09062024\">Clean Solutions LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations I","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Asim Ozcan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Clean Solutions LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>791 Paulison Ave., Suite 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Clifton\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07011-3608\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:asim@cleansolutionsnj.com\"> asim@cleansolutionsnj.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003Cbr>\nCMS #686995\u003C\u002Fp>\n\n\u003Cp>9\u002F6\u002F2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Ozcan:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Clean Solutions LLC, FEI 3012305678, at 791 Paulison Ave., Suite 5, Clifton, NJ, from May 6 to 10, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your May 29, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) topical drug products, such as antibacterial hand soaps containing benzalkonium chloride. You failed to perform adequate identity testing of each component lot used in the manufacture of your drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to perform appropriate testing on your hand sanitizer and antibacterial hand soap drug products prior to release for distribution. Specifically, during the inspection, you stated that no chemical or microbiological analyses are performed on your finished drug products.\u003C\u002Fp>\n\n\u003Cp>Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to validate the processes used to manufacture your drug products. You also failed to qualify the equipment used to manufacture your drug products.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>Without adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cp>• Establishment of adequate procedures describing complaint handling, change control, and employee training procedures (21 CFR 211.22(d)).\u003Cbr>\n• Establishment of an adequate ongoing stability program (21 CFR 211.166(a)).\u003Cbr>\n• Performance of periodic (i.e., at least annual) product reviews (21 CFR 211.180(e)).\u003Cbr>\n• Adequate equipment cleaning and cleaning procedures, as well as appropriate cleaning validation (21 CFR 211.67(a) and 67(b)).\u003Cbr>\n• Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).\u003C\u002Fp>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In response to this letter, clarify whether you intend to continue manufacturing drugs at this or any other facility.\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if you continue manufacturing drugs. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003Cbr>\n\u003Cbr>\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to orapharm1_responses@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 686995 and include FEI: 3012305678.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, contact Compliance Officer Barbara Wilimczyk-Macri at barbara.wilimczyk@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nOPQO Division I\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Asim Ozcan\n\nRecipient Title\n\nPresident\n\nClean Solutions LLC\n\n791 Paulison Ave., Suite 5\n\nClifton, NJ 07011-3608\n\nUnited States\n\nasim@cleansolutionsnj.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter\n\nCMS #686995\n\n9\u002F6\u002F2024\n\nDear Mr. Ozcan:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Clean Solutions LLC, FEI 3012305678, at 791 Paulison Ave., Suite 5, Clifton, NJ, from May 6 to 10, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your May 29, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYour firm manufactures over-the-counter (OTC) topical drug products, such as antibacterial hand soaps containing benzalkonium chloride. You failed to perform adequate identity testing of each component lot used in the manufacture of your drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\n\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products.\n\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\n\nYour firm failed to perform appropriate testing on your hand sanitizer and antibacterial hand soap drug products prior to release for distribution. Specifically, during the inspection, you stated that no chemical or microbiological analyses are performed on your finished drug products.\n\nTesting is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\n\n3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou failed to validate the processes used to manufacture your drug products. You also failed to qualify the equipment used to manufacture your drug products.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\n\nWithout adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\n• Establishment of adequate procedures describing complaint handling, change control, and employee training procedures (21 CFR 211.22(d)).\n\n• Establishment of an adequate ongoing stability program (21 CFR 211.166(a)).\n\n• Performance of periodic (i.e., at least annual) product reviews (21 CFR 211.180(e)).\n\n• Adequate equipment cleaning and cleaning procedures, as well as appropriate cleaning validation (21 CFR 211.67(a) and 67(b)).\n\n• Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nIn response to this letter, clarify whether you intend to continue manufacturing drugs at this or any other facility.\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if you continue manufacturing drugs. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic response to orapharm1_responses@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 686995 and include FEI: 3012305678.\n\nIf you have any questions, contact Compliance Officer Barbara Wilimczyk-Macri at barbara.wilimczyk@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nOPQO Division I\n\nU.S. Food and Drug Administration","Clean Solutions LLC","clean-solutions-llc-686995-09062024","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fclean-solutions-llc-686995-09062024","2026-10-26T08:08:15.745138+00:00","2024-10-01","686995","Mr. Asim Ozcan","2026-08-19T22:31:53.814+00:00","2024-09-06",{"id":187,"raw":188,"subject":131,"body_html":193,"body_text":194,"firm_name":195,"letter_id":196,"created_at":18,"fei_number":19,"letter_url":197,"updated_at":198,"action_type":22,"case_status":23,"posted_date":199,"marcs_cms_no":19,"product_type":26,"closeout_date":19,"issuing_office":192,"recipient_name":200,"body_fetched_at":201,"delivery_method":70,"recipient_title":19,"reference_number":19,"action_taken_date":202,"medical_device_id":19,"response_letter_date":19},2916,[189,190,191,192,131,13,13,13],"\u003Ctime datetime=\"2022-01-18T14:20:00Z\">01\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-20T04:00:00Z\">09\u002F20\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapothecary-health-solutionsright-value-drug-stores-llc-dba-carie-boyds-prescription-shop-610751\">Apothecary Health Solutions\u002FRight Value Drug Stores, LLC dba Carie Boyd&#039;s Prescription Shop\u003C\u002Fa>","Office of Pharmaceutical Quality Operations, Division II","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Evan Gilbert\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Apothecary Health Solutions\u002FRight Value Drug Stores, LLC dba Carie Boyd's Prescription Shop\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2501 W Oak Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Denton\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:egilbert@apothecaryhealth.com\"> egilbert@apothecaryhealth.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Pharmaceutical Quality Operations, Division II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 20, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Case # 610751\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Mr. Gilbert:\u003C\u002Fp>\n\n\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on July 3, 2019 and most recently on November 19, 2020. From October 28, 2019 to November 12, 2019, an FDA investigator inspected your facility, Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop located at 8400 Esters Blvd, Suite 190, Irving, Texas 75063. During the inspection, the investigator noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your facility on November 12, 2019. FDA acknowledges receipt of your facility’s responses, dated November 29, 2019 and December 31, 2019, as well as your subsequent correspondence. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>An outsourcing facility, as defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>In addition, for a compounded drug product to qualify for exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\u003C\u002Fp>\n\n\u003Cp>Furthermore, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b) including the requirement to submit a report to FDA upon initially registering as an outsourcing facility, once in June of each year, and once in December of each year identifying the drug products compounded during the previous 6-month period (section 503B(b)(2) of the FDCA [21 U.S.C. §353b(b)(2)]) and the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations” (section 503B(b)(5) of the FDCA [21 U.S.C. § 353b(b)(5)]).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503B\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, the FDA investigator noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigator noted:\u003C\u002Fp>\n\n\u003Cp>1. Some of your facility’s drug products did not include the National Drug Code number on the label (section 503B(a)(10)(A)(iii)(VIII) of the FDCA [21 U.S.C. § 353b(a)(10)(A)(iii)(VIII)]). For example, the drug product labels for Estradiol Pellet 6mg (NDC 71138-0006-01) and Testosterone Pellet 25mg (NDC 71138-1025-01) did not include the National Drug Code numbers. In addition, the container from which individual units of some of your facility’s drug products are removed for dispensing or for administration, including Estradiol Pellet 6mg and Testosterone Pellet 25mg, did not include directions for use (section 503B(a)(10)(B)(iii)) of the FDCA [21 U.S.C. §353b(a)(10)(B)(iii)]).\u003C\u002Fp>\n\n\u003Cp>2. The report your facility submitted to FDA upon initial registration, in July 2019, failed to identify all the drug products that you compounded during the previous 6-month period, including HCG Methylcobalamin B12 1000IU Injection, Testosterone Pellets-25mg, 37.5mg, 50mg, 100mg, &amp; 200mg, Estradiol Pellets-6mg, 10mg, 12.5mg, &amp; 15mg, Testosterone\u002FAnastrozole Pellets-75mg\u002F4mg &amp; 100mg\u002F4mg and Testosterone cypionate\u002F Testosterone propionate 200mg\u002F10mg Injection.\u003C\u002Fp>\n\n\u003Cp>3. Your facility failed to submit adverse event reports to FDA as required by section 503B(b)(5) and 21 CFR 310.305. Specifically, FDA received a report of an adverse drug experience from your firm on October 31, 2019, regarding a patient who was diagnosed with \u003Cstrong>(b)(6)\u003C\u002Fstrong>&nbsp;after administration of your compounded Testosterone 25mg, Testosterone 50mg, and Testosterone 87.5 mg pellets. However, your firm became aware of this adverse drug experience on September 26, 2019. An outsourcing facility must submit to FDA reports of all serious, unexpected adverse drug experiences associated with their compounded drug products as soon as possible, but no later than 15 calendar days after first receiving information about the adverse drug experience (21 CFR 310.305(c)(1)).\u003C\u002Fp>\n\n\u003Cp>Because your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You do not have any FDA-approved applications on file for drug products that you compound.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 355(a) and 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to Report Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As noted above, your facility failed to submit a complete report to FDA upon initial registration as an outsourcing facility in July 2019, identifying all the drug products that you compounded during the previous 6-month period (section 503B(b)(2) of the FDCA). The failure to report drugs by an entity that is registered with FDA in accordance with section 503B(b) is a prohibited act under section 301(ccc)(3) of the FDCA [21 U.S.C. § 331(ccc)(3)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Failure to Report Adverse Events\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As noted above, your facility failed to submit adverse event reports in accordance with section 503B(b) and 21 CFR 310.305. The failure to report adverse events by an entity that is registered with FDA in accordance with section 503B(b) is a prohibited act under section 301(ccc)(3) of the FDCA [21 U.S.C. § 331(ccc)(3)].\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your facility’s responses to the Form FDA 483 and your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>Regarding issues related to the conditions of section 503B of the FDCA, some of your corrective actions appear adequate:\u003C\u002Fp>\n\n\u003Cp>1. The product report submitted in December 2019 appears to identify all the drug products that you compounded during the previous 6-month period, including the products not reported upon initial registration in July 2019.\u003C\u002Fp>\n\n\u003Cp>2. You provided documentation of a “revised Adverse Drug Event (ADE) SOP to include calendar invitations…to ensure report is submitted within 15-day requirement” and [r]etrained all employees on [this] ADE SOP.” Please note that we are unable to fully evaluate whether the aforementioned SOP is consistent with the content and format requirements established through regulation under section 310.305 of title 21, Code of Federal Regulations, because the documentation provided is incomplete.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>However, you did not address labeling issues related to the conditions of section 503B of the FDCA. FDA reminds you that drug products produced in a 503B-registered outsourcing facility must be labeled in accordance with section 503B as one of the conditions necessary to qualify for the exemptions under section 503B of the FDCA (Section 503B(a)(10), [21 U.S.C. § 353b(a)(10)]).\u003C\u002Fp>\n\n\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\u003C\u002Fp>\n\n\u003Cp>Furthermore, during the inspection, the FDA investigator noted that your facility compounded drug products that are (1) not identical or nearly identical to an approved drug product and (2) the component of which is a bulk drug substance that is a component of an approved drug product.\u003C\u002Fp>\n\n\u003Cp>Please be advised that FDA intends to consider such products to be essentially a copy of an approved drug product under section 503B(d)(2)(B) of the FDCA unless the prescribing practitioner determines that there is a change that produces a clinical difference for an individual patient. If you intend to rely on such a determination to establish that a compounded drug is not essentially a copy of an approved drug, you should ensure that the determination is noted on the prescription or order (which may be a patient-specific prescription or a non-patient specific order) for the compounded drug.\u003C\u002Fp>\n\n\u003Cp>We do acknowledge your firm’s intention to not compound drug products that are essentially a copy of one or more approved drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003Cbr>\n\u003Cbr>\nYou should take prompt action to correct any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe that your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so. Your written notification should refer to the Warning Letter Number above (Case # 610751). Please electronically submit your signed reply on your firm’s letterhead to CDR John W. Diehl, M.S., Director, Compliance Branch, at john.diehl@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Tamala Bogan\u003Cbr>\nActing Program Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>cc:\u003C\u002Fp>\n\n\u003Cp>Via Electronic Mail\u003Cbr>\nDonald Prentiss, President of Operations\u003Cbr>\nRight Value Drug Stores, LLC dba Carie Boyd's Prescription Shop\u003Cbr>\n8400 Esters Blvd, Suite 190\u003Cbr>\nIrving, Texas 75063-2217\u003Cbr>\n\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Ann Driscoll, Director of Operations\u003Cbr>\nTexas State Board of Pharmacy\u003Cbr>\n333 Guadalupe Street, Suite 3-500\u003Cbr>\nAustin, Texas 78701-3943\u003Cbr>\nann.driscoll@pharmacy.texas.gov\u003C\u002Fp>\n\n\u003Cp>_______________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf\">https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf\u003C\u002Fa>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nEvan Gilbert\n\nRecipient Title\n\nCEO\n\nApothecary Health Solutions\u002FRight Value Drug Stores, LLC dba Carie Boyd's Prescription Shop\n\n2501 W Oak Street\n\nDenton, TX 76201\n\nUnited States\n\negilbert@apothecaryhealth.com\n\nIssuing Office:\n\nOffice of Pharmaceutical Quality Operations, Division II\n\nUnited States\n\nSeptember 20, 2021\n\nCase # 610751\n\nWARNING LETTER\n\nMr. Gilbert:\n\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on July 3, 2019 and most recently on November 19, 2020. From October 28, 2019 to November 12, 2019, an FDA investigator inspected your facility, Right Value Drug Stores, LLC dba Carie Boyd's Prescription Shop located at 8400 Esters Blvd, Suite 190, Irving, Texas 75063. During the inspection, the investigator noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA.\n\nFDA issued a Form FDA 483 to your facility on November 12, 2019. FDA acknowledges receipt of your facility’s responses, dated November 29, 2019 and December 31, 2019, as well as your subsequent correspondence. Based on this inspection, it appears you produced drugs that violate the FDCA.\n\nA. Compounded Drug Products under the FDCA\n\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.2\n\nAn outsourcing facility, as defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\n\nIn addition, for a compounded drug product to qualify for exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\n\nFurthermore, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b) including the requirement to submit a report to FDA upon initially registering as an outsourcing facility, once in June of each year, and once in December of each year identifying the drug products compounded during the previous 6-month period (section 503B(b)(2) of the FDCA [21 U.S.C. §353b(b)(2)]) and the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations” (section 503B(b)(5) of the FDCA [21 U.S.C. § 353b(b)(5)]).\n\nB. Failure to Meet the Conditions of Section 503B\n\nDuring the inspection, the FDA investigator noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigator noted:\n\n1. Some of your facility’s drug products did not include the National Drug Code number on the label (section 503B(a)(10)(A)(iii)(VIII) of the FDCA [21 U.S.C. § 353b(a)(10)(A)(iii)(VIII)]). For example, the drug product labels for Estradiol Pellet 6mg (NDC 71138-0006-01) and Testosterone Pellet 25mg (NDC 71138-1025-01) did not include the National Drug Code numbers. In addition, the container from which individual units of some of your facility’s drug products are removed for dispensing or for administration, including Estradiol Pellet 6mg and Testosterone Pellet 25mg, did not include directions for use (section 503B(a)(10)(B)(iii)) of the FDCA [21 U.S.C. §353b(a)(10)(B)(iii)]).\n\n2. The report your facility submitted to FDA upon initial registration, in July 2019, failed to identify all the drug products that you compounded during the previous 6-month period, including HCG Methylcobalamin B12 1000IU Injection, Testosterone Pellets-25mg, 37.5mg, 50mg, 100mg, & 200mg, Estradiol Pellets-6mg, 10mg, 12.5mg, & 15mg, Testosterone\u002FAnastrozole Pellets-75mg\u002F4mg & 100mg\u002F4mg and Testosterone cypionate\u002F Testosterone propionate 200mg\u002F10mg Injection.\n\n3. Your facility failed to submit adverse event reports to FDA as required by section 503B(b)(5) and 21 CFR 310.305. Specifically, FDA received a report of an adverse drug experience from your firm on October 31, 2019, regarding a patient who was diagnosed with (b)(6) after administration of your compounded Testosterone 25mg, Testosterone 50mg, and Testosterone 87.5 mg pellets. However, your firm became aware of this adverse drug experience on September 26, 2019. An outsourcing facility must submit to FDA reports of all serious, unexpected adverse drug experiences associated with their compounded drug products as soon as possible, but no later than 15 calendar days after first receiving information about the adverse drug experience (21 CFR 310.305(c)(1)).\n\nBecause your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\n\nSpecific violations are described below.\n\nC. Violations of the FDCA\n\nUnapproved New Drug Products\n\nYou do not have any FDA-approved applications on file for drug products that you compound.3 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 355(a) and 331(d)], a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\n\nMisbranded Drug Products\n\nYou compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.4 The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\n\nFailure to Report Drugs\n\nAs noted above, your facility failed to submit a complete report to FDA upon initial registration as an outsourcing facility in July 2019, identifying all the drug products that you compounded during the previous 6-month period (section 503B(b)(2) of the FDCA). The failure to report drugs by an entity that is registered with FDA in accordance with section 503B(b) is a prohibited act under section 301(ccc)(3) of the FDCA [21 U.S.C. § 331(ccc)(3)].\n\nFailure to Report Adverse Events\n\nAs noted above, your facility failed to submit adverse event reports in accordance with section 503B(b) and 21 CFR 310.305. The failure to report adverse events by an entity that is registered with FDA in accordance with section 503B(b) is a prohibited act under section 301(ccc)(3) of the FDCA [21 U.S.C. § 331(ccc)(3)].\n\nD. Corrective Actions\n\nWe have reviewed your facility’s responses to the Form FDA 483 and your subsequent correspondence.\n\nRegarding issues related to the conditions of section 503B of the FDCA, some of your corrective actions appear adequate:\n\n1. The product report submitted in December 2019 appears to identify all the drug products that you compounded during the previous 6-month period, including the products not reported upon initial registration in July 2019.\n\n2. You provided documentation of a “revised Adverse Drug Event (ADE) SOP to include calendar invitations…to ensure report is submitted within 15-day requirement” and [r]etrained all employees on [this] ADE SOP.” Please note that we are unable to fully evaluate whether the aforementioned SOP is consistent with the content and format requirements established through regulation under section 310.305 of title 21, Code of Federal Regulations, because the documentation provided is incomplete.5\n\nHowever, you did not address labeling issues related to the conditions of section 503B of the FDCA. FDA reminds you that drug products produced in a 503B-registered outsourcing facility must be labeled in accordance with section 503B as one of the conditions necessary to qualify for the exemptions under section 503B of the FDCA (Section 503B(a)(10), [21 U.S.C. § 353b(a)(10)]).\n\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\n\nFurthermore, during the inspection, the FDA investigator noted that your facility compounded drug products that are (1) not identical or nearly identical to an approved drug product and (2) the component of which is a bulk drug substance that is a component of an approved drug product.\n\nPlease be advised that FDA intends to consider such products to be essentially a copy of an approved drug product under section 503B(d)(2)(B) of the FDCA unless the prescribing practitioner determines that there is a change that produces a clinical difference for an individual patient. If you intend to rely on such a determination to establish that a compounded drug is not essentially a copy of an approved drug, you should ensure that the determination is noted on the prescription or order (which may be a patient-specific prescription or a non-patient specific order) for the compounded drug.\n\nWe do acknowledge your firm’s intention to not compound drug products that are essentially a copy of one or more approved drug products.\n\nE. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to correct any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you believe that your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so. Your written notification should refer to the Warning Letter Number above (Case # 610751). Please electronically submit your signed reply on your firm’s letterhead to CDR John W. Diehl, M.S., Director, Compliance Branch, at john.diehl@fda.hhs.gov and orapharm2_responses@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Mr. Thao Ta, Compliance Officer, via phone at 214-253-5217 or e-mail at thao.ta@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTamala Bogan\n\nActing Program Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\ncc:\n\nVia Electronic Mail\n\nDonald Prentiss, President of Operations\n\nRight Value Drug Stores, LLC dba Carie Boyd's Prescription Shop\n\n8400 Esters Blvd, Suite 190\n\nIrving, Texas 75063-2217\n\n(b)(6)\n\nAnn Driscoll, Director of Operations\n\nTexas State Board of Pharmacy\n\n333 Guadalupe Street, Suite 3-500\n\nAustin, Texas 78701-3943\n\nann.driscoll@pharmacy.texas.gov\n\n_______________________________________\n\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n\n3 The specific products made by your firm are drugs within the meaning of section 201(g) of the Act, [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n4 Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\n\n5 See FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf.","Apothecary Health Solutions\u002FRight Value Drug Stores, LLC dba Carie Boyd's Prescription Shop","apothecary-health-solutionsright-value-drug-stores-llc-dba-carie-boyds-prescription-shop-610751","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fapothecary-health-solutionsright-value-drug-stores-llc-dba-carie-boyds-prescription-shop-610751","2026-10-26T08:07:56.655298+00:00","2022-01-18","Evan Gilbert","2026-08-20T02:15:18.388+00:00","2021-09-20",10,{"510k":205,"classification":206,"enforcement":207,"event":208,"event_backfill":209,"pma":210,"warning_letter":211},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]